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ABSTRACT 
 
Meagan Bridget Ryan: Targeting the ERK MAPK cascade in RAS-driven cancers 
(Under the direction of Adrienne D. Cox and Channing J. Der) 
 
 RAS mutations are frequently found in the deadliest cancers in the United 
States, and there is a renewed interest in identifying therapeutic strategies to target 
RAS-driven cancers. While recent strategies to directly target mutant RAS have 
identified provocative small molecules, whether these can be developed into 
clinically potent and selective drugs remains to be seen.  Arguably, among the most 
promising directions have been efforts to target protein kinase components of the 
effector pathways downstream of RAS. One of the best characterized effector 
pathways is the ERK mitogen-activated protein kinase (MAPK) cascade, a pathway 
that is critical in both the initiation and maintenance of NRAS- and BRAF-mutant 
melanoma as well as KRAS-mutant pancreatic ductal adenocarcinoma (PDAC). My 
research has focused on two aspects of the ERK MAPK cascade in these cancers: 
ERK regulation of the RAC small GTPase guanine nucleotide exchange factor 
(RACGEF) PREX1 in melanoma, and synergy between p38 MAPK and ERK 
inhibitors in PDAC. 
 My studies in melanoma are focused on the RacGEF PREX1, a protein that 
has been previously identified as a driver of metastasis in an NRAS-driven 
genetically engineered mouse model of cancer. PREX1 is an activator of RAC1, also 
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mutationally activated in melanoma.  Previous work from our lab identified PREX1 
as one of 82 genes regulated downstream of the ERK MAPK pathway in BRAF-
mutant melanomas. Our lab also found that mice deficient in Prex1 were impaired in 
Nras-driven melanoma metastasis. My work has extended these studies on PREX1 
to a broader panel of both NRAS- and BRAF-mutant melanomas. I found that 
expression of PREX1 protein is elevated in malignant melanomas compared to 
benign nevi and that high PREX1 protein expression is correlated with high levels of 
phosphorylated ERK. Loss of PREX1 reduced invasion in a context dependent 
manner and reduced levels of active RAC1-GTP, but not of the related GTPase 
CDC42.  Also, the expression of PREX1 was regulated by ERK both transcriptionally 
and post-translationally. I found that the mechanisms of ERK driven overexpression 
of PREX1 in melanomas differs from those of PREX1 regulation previously identified 
in prostate cancer and breast cancer. Finally, my studies provide a mechanistic 
basis for a connection between the ERK MAPK cascade and RAC1, two pathways 
critical for the maintenance of melanomas. Since ERK MAPK pathway inhibitors are 
currently the standard of care in BRAF mutant melanomas, this connection warrants 
further study, especially in the context of therapeutic resistance. 
 Therapeutic resistance to ERK MAPK cascade inhibition arises not only in 
BRAF-mutant melanomas, but also in other cancers driven by activation of the ERK 
MAPK cascade.  KRAS-mutant pancreatic cancer is the third deadliest cancer in the 
United States and is dependent on the ERK MAPK cascade for both tumor 
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development and maintenance. A recent study from our group found that a subset of 
KRAS-mutant PDAC cell lines and tumors are sensitive to the ERK inhibitors 
SCH772984 and BVD-523. I sought to validate a resistance mechanism to ERK 
inhibition first identified by this study, MAPK14 (p38α). Similar to ERK, p38 is the 
terminal kinase of a three-tiered MAPK cascade. We employed a novel 
CRISPR/Cas9 screen to identify mechanisms of resistance to the ERK inhibitor 
SCH772984 in KRAS-mutant pancreatic, lung, and colorectal cancers. MAPK14 was 
identified as a sensitizer to ERK inhibition and I validated that pharmacologic 
inhibition of p38 with the clinical candidate p38α/β inhibitor LY2228820 also 
sensitized PDAC to ERK inhibition. Concurrent p38 inhibition sensitized PDAC cell 
lines to the ERK inhibitors SCH772984 and BVD-523 in both anchorage-dependent 
and anchorage-independent growth. Concurrent p38 and ERK inhibition also led to 
an increase in G0/G1 cell cycle arrest vs ERK inhibitor treatment alone, while no 
enhancement in apoptosis was seen with dual inhibition vs ERK inhibitor alone. 
Mechanistically, ERK inhibitor treatment induced activation of the p38 MAPK 
cascade, including induction of expression of the p38 downstream substrate HSP27. 
Finally, concurrent p38 and ERK inhibition also enhanced loss of MYC, an oncogene 
critical for maintaining PDAC growth and previously identified by our group as a 
marker of sensitivity or resistance to ERK inhibition. My studies provide a 
mechanistic basis for synergy between p38 and ERK inhibition in PDAC that can be 
extended to additional KRAS-mutant cancers. 
 In summary, my studies provide a rationale for the importance of the ERK 
MAPK cascade in RAS-driven cancers. ERK plays many roles in initiating and 
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maintaining tumors of diverse genetic backgrounds, encompassing NRAS, KRAS, 
and BRAF mutations. Finally, my studies reveal the value in direct pharmacologic 
inhibition of ERK in RAS-driven cancers and in understanding resistance 
mechanisms to enhance ERK inhibitor therapeutic benefit. 
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To my father, who fought bravely not once, but twice against cancer. 
I will continue your fight. 
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Chapter I: INTRODUCTION1 
ADAPTED FROM: Targeting RAS-mutant cancers: Is ERK the key? 
 
Introduction 
 
 The three RAS genes comprise the most frequently mutated oncogene family 
in cancer. With significant and compelling evidence that continued function of mutant 
RAS is required for tumor maintenance, it is widely accepted that effective anti-RAS 
therapy will have a significant impact on cancer growth and patient survival. 
However, despite more than three decades of intense research and pharmaceutical 
industry efforts, a clinically effective anti-RAS drug has yet to be developed.  With 
the recent renewed interest in targeting RAS, exciting and promising progress has 
been made. My dissertation studies focused on inhibiting the RAF-MEK-ERK 
cascade in NRAS- and BRAF-mutant melanoma and the role it plays in regulating 
expression of the RacGEF PREX1, as described in Chapter 2, and on identification 
of a potential resistance mechanism to direct ERK inhibition in KRAS-mutant PDAC, 
as described in Chapter 3.  Below, these studies are placed into the larger context of 
the prospects and challenges of drugging oncogenic RAS. In particular I focus here 
on new inhibitors of RAS effector signaling and on the ERK mitogen-activated 
protein kinase cascade.   
                                                          
1
 This Chapter is adapted from previously published work.  Authors are Meagan B. Ryan, Channing J. 
Der, Andrea Wang-Gillam, and Adrienne D. Cox 
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RAS:  in fashion, again 
 
The discoveries in 1982 that human RAS genes are mutationally activated in 
cancer (Figure 1-1) initiated intensive efforts to identify pharmacological strategies 
that could disrupt the aberrant function of the corresponding RAS proteins[1].  Two 
decades later, when it became disappointingly apparent that farnesyltransferase 
inhibitors (FTIs) were not the answer, enthusiasm diminished dramatically.  This 
failure coincided with the dawn of the current post-genomic era of cancer research, 
when sequencing of the cancer genome began to reveal the complexities of the 
genetic basis of cancer[2,3]. What these studies did not yield, however, were 
attractive new targets for cancer drug discovery.  Instead, exome sequencing of 
colorectal, lung and pancreatic cancers verified that RAS mutations are the most 
prevalent gain-of-function genetic alterations in the cancers that comprise three of 
the top four causes of cancer deaths in the United States[2-4].  With this reality check, 
it became apparent that further efforts to seek an effective anti-RAS therapy, long an 
elusive holy grail of cancer research, must become a renewed priority, however 
difficult the task[5].  In this review, we provide an overview and perspective on the 
most promising directions for these efforts.  We then focus on the direction where 
the greatest promise lies in the near future:  with inhibitors already under clinical 
evaluation, there is guarded optimism that blocking RAS effector signaling may 
produce a clinically effective anti-RAS drug.  In particular, we focus on the prospects 
and challenges faced by inhibitors of what is arguably the most significant signaling 
network driving cancer growth, the RAF-MEK-ERK protein kinase cascade. 
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Targeting RAS in cancer 
 
The three RAS genes (HRAS, NRAS and KRAS) comprise the most 
frequently mutated gene family in cancer, with KRAS by far the most commonly 
mutated of these[2,3] (Figure 1-2a).  There is substantial experimental evidence in cell 
culture and mouse model studies that mutant RAS is a critical driver of cancer 
initiation and maintenance.  Thus, an effective anti-RAS therapy is expected to 
significantly impact cancer growth. Oncogenic RAS mutations are typically found in 
hotspots critical for the GTP/GDP on-off switch (Figure 1-2b), so the mutated RAS 
proteins escape normal regulation and are constitutively GTP-bound and active 
(Figure 1-2c).  Unlike the successful development of ATP-competitive inhibitors of 
protein kinases, similar strategies to disrupt persistent GTP binding to mutant RAS 
have been seen as unsuccessful due to the apparent high picomolar binding 
affinities of RAS for GTP. Moreover, the smooth topology of RAS proteins originally 
discouraged efforts to search for small molecules that bound RAS directly, 
prompting perceptions that RAS is “undruggable”. Yet recent intriguing success in 
this area includes identification of cell- active small molecules that do bind directly to 
RAS and disrupt RAS interaction with regulators and/or effectors[6-8]. Particularly 
significant are the small molecules that target a specific KRAS mutation (G12C)[9,10], 
although it remains uncertain as to whether these can be advanced to clinically 
active and selective inhibitors of mutant RAS.    
 In addition to the challenging attempts to directly inhibit RAS itself, four 
approaches to inhibit RAS involve indirect targeting of proteins that support mutant 
RAS function (Figure 1-3). These approaches include: i) Inhibition of RAS-
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membrane association. RAS proteins undergo posttranslational modification and 
covalent addition of prenyl and fatty acid lipids that promote association with the 
plasma membrane[11]. Inhibitors of the enzyme farnesyltransferase (FTIs) effectively 
disrupt plasma membrane association of HRAS, but not KRAS or NRAS. Therefore, 
it was not surprising that FTIs were clinically ineffective in pancreatic and colon 
cancer, where there is nearly exclusive mutation of KRAS.  Another recent approach 
is to inhibit phosphodiesterase delta (PDEδ), a chaperone that is thought to facilitate 
RAS membrane trafficking[12].  A potential limitation of these approaches is that the 
proteins targeted also support the functions of numerous other proteins; ii) Inhibition 
of synthetic lethality interaction. Functional genetic screens have identified synthetic 
lethal interactors of mutant RAS, proteins whose functions are critical only in the 
context of RAS-mutant cancer cells[13].  However, the initial excitement in this area 
was dampened considerably when follow-up analyses failed to support the strong 
association of these proteins specifically with mutant RAS.  Despite mixed opinions 
on the ultimate promise of this direction, ongoing studies still seek to improve the 
methodologies and biological screens in hopes of overcoming earlier limitations; iii) 
Inhibition of RAS-regulated metabolic processes. A recent new direction has been 
prompted by findings that mutant RAS function deregulates cellular processes (e.g., 
autophagy, glucose and glutamine metabolism) that support the increased metabolic 
needs of cancer cells[14]. These efforts are still in their infancy, with attractive targets 
and selective inhibitors for those targets still to be developed. A key limitation of the 
latter three approaches is that these proteins do not support RAS function 
exclusively and hence, their inhibition can have significant non-RAS cellular effects.  
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Currently, the area with the most advanced activity is the iv) Inhibition of RAS 
effector signaling. Numerous candidate inhibitors are presently under clinical 
evaluation, including inhibitors of the RAF and PI3K effector pathways[3] (RAF-MEK-
ERK inhibitors detailed in Table 1).  While conceptually simple, in practice this 
approach is complicated by the diversity of RAS downstream signaling networks, 
extensive signaling crosstalk and the highly dynamic nature of these networks.  In 
this review, we ask, "Can inhibitors of the RAF-MEK-ERK mitogen-activated protein 
kinase (MAPK) cascade fulfill the promise of targeting RAS?".  
 
The RAF-MEK-ERK cascade:  sufficient and necessary for mutant RAS-driven 
tumor development 
 
 Active RAS-GTP can bind to and regulate a spectrum of catalytically diverse 
effectors (Figure 1-2c). Of these, the three-tiered RAF-MEK-ERK protein kinase 
cascade is the best characterized and validated driver of normal and mutant RAS 
function (Figure 1-4). The RAF-MEK-ERK cascade is under tight spatio-temporal 
regulation, dictating both quantitative and qualitative differences in ERK signaling 
output and biological outcomes. Among the numerous ERK substrates are 
components that comprise negative feedback mechanisms to attenuate the strength 
of ERK signaling.  While ERK activation generally stimulates growth, excessive ERK 
activation can instead cause growth arrest[15]. Thus, finely tuned dynamic regulation 
of signaling flux through this cascade is critical in dictating the cellular consequences 
of ERK activation.  Accordingly, there are diverse mechanisms of ERK feedback 
inhibition (Figure 1-5). One key mechanism involves ERK phosphorylation of CRAF  
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and BRAF, thereby decreasing RAF dimerization and association with activated 
RAS[16].   
The importance of the RAF-MEK-ERK cascade as a therapeutic target in 
cancer is supported by several lines of evidence.  BRAF is frequently mutationally 
activated (19%; COSMIC).  The non-overlapping occurrence of RAS and BRAF 
mutations in cancer types where both are found is consistent with equivalent driver 
roles for each activated oncogene. Supporting a key driver role of BRAF in KRAS-
driven oncogenesis, mutationally activated BrafV600E but not Pik3ca1047R was 
sufficient to phenocopy activated KrasG12D in a mouse model of pancreatic cancer, 
and to induce pancreatic ductal adenocarcinoma together with mutant Tp53R270H[17].  
Genetic ablation of components of this pathway further supports the therapeutic 
value of targeting each level of this cascade. For example, in a Kras-driven mouse 
model of lung tumorigenesis, loss of either Mek1 or Mek2 increased survival by 
~20%, while loss of both genes induced a near 100% increase in survival[18].  Also, 
the loss of Erk1 or Erk2 increased survival by 20% and 16%, respectively, and deficit 
of both genes increased survival by 40%[18].  More importantly, the few tumors that 
did arise in the Erk1 null background were "escapers" that continued to express 
Erk2[18].  However, the complete genetic ablation of both Erk1 and Erk2 was 
deleterious for normal adult tissue homeostasis[18].  Genetic ablation of Craf alone 
(but not Braf) impaired mutant Kras-driven lung tumor formation and increased 
survival[18,19].  However, Craf deficiency did not impair mutant Kras-driven pancreatic 
cancer development, indicating that there are cancer-type differences in RAF 
isoform dependencies[20].  These genetic studies support both the sufficiency and 
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necessity of the RAF-MEK-ERK cascade in mutant RAS-driven tumor initiation and 
progression. However, since each MAPK component was ablated concurrently with 
RAS activation, their requirement in tumor maintenance was not addressed. 
Additionally, genetic loss of an entire protein may not accurately model the 
consequences of the pharmacologic inhibition of its catalytic kinase domain and 
activity. How far along is the development of RAF-MEK-ERK inhibitors and how are 
these drugs performing in the clinic?  
RAF Inhibitors 
 
 The FDA-approved drug sorafenib was developed originally as an ATP-
competitive CRAF inhibitor, but its clinical efficacy is attributed to its unspecific multi-
kinase inhibitory activity, particularly the inhibition of receptor tyrosine kinases 
(RTKs) that drive tumor angiogenesis [21]. While sorafenib can inhibit ERK signaling, 
the degree of ERK inhibition may not be sufficient for effective suppression of ERK-
driven cancer growth[21]. Second generation ATP-competitive BRAF-selective 
inhibitors, vemurafenib and dabrafenib, have been approved by the FDA for use in 
BRAF-mutant malignant melanoma and lead to clinically significant progression-free 
and overall survival[22-24].  However, while both cause initial rapid tumor regression in 
70 to 80% of BRAF-mutant melanoma patients, mechanisms of resistance leading to 
relapse also occur rapidly in the majority of cases. Additionally, many BRAF-mutant 
colorectal, thyroid, and lung cancers exhibit de novo resistance to these BRAF-
selective inhibitors[25].  Identifying resistance mechanisms will therefore be critical to 
more effectively applying these inhibitors in the clinic. 
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Much of the information regarding mechanisms that drive de novo and/or 
acquired resistance to inhibitors of RAF-MEK-ERK inhibition (Figure 1-6) comes 
from cell culture experiments in which resistance is induced by long-term treatment  
with inhibitors. These mechanisms include activation of upstream components (e.g., 
NRAS mutation, NF1 inactivation, increased RTK expression and/or activation)[26,27] 
or increased RAF activity (via truncation and increased BRAF dimerization or 
increased BRAF expression) that lead to ERK reactivation. Since more than 80% 
suppression of ERK is required for a clinical response[28], increased flux through the 
cascade and increased ERK activation is sufficient to render cancer cells drug-
insensitive. Other resistance mechanisms that reactivate the pathway downstream 
of the inhibitor blockade include activating mutations in MEK1 and MEK2[29] or 
amplification of TPL2/COT[30], which phosphorylates and activates MEK1/2. 
Additional mechanisms that do not restore ERK activation, but that instead decrease 
dependency on ERK-driven growth, include activation of PI3K-AKT-mTOR signaling 
and mutational activation of the small GTPase RAC1[31,32].  The clinical significance 
of some mechanisms remains to be established. 
 In contrast to their efficacy in BRAF-mutant cancers, vemurafenib and 
dabrafenib not only are ineffective in RAS-mutant cancers, but instead stimulate 
their growth[33-37]. This effect is due to paradoxical activation, rather than inhibition, of 
ERK.  In this setting, drug-inactivated BRAF forms a heterodimer with drug-free 
CRAF that complexes with mutant RAS, which causes allosteric activation of CRAF 
by the inactive BRAF dimerization partner, thereby increasing ERK signaling (Figure 
1-6).  
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Third-generation BRAF inhibitors (Table 1) are not limited by this activation 
and are known as "paradox breakers"., Currently, there is one paradox-breaker 
inhibitor, PLX8394, in clinical Phase I evaluation (NCT02428712). Compared to 
vemurafenib, PLX8394 has unique binding sites in the BRAF activation site and is 
also a superior inhibitor of CRAF[38,39].  PLX8394 can also effectively block ERK 
activation and the growth of RAS-mutant vemurafenib-resistant melanoma cells[39].  
Pan-RAF inhibitors -MLN2480, HM95573 and LY3009120- have also entered Phase 
I trials[40-42].  LY3009120 has shown in vitro and in vivo efficacy in inhibiting the ERK 
pathway without eliciting the effect of paradoxical activation [42].  An alternative 
strategy for effective RAF inhibition in RAS-mutant cancers may be the use of small 
molecule inhibitors of RAF dimerization[43].  While these strategies can overcome 
upstream signaling resistance mechanisms, they will still be, however, susceptible to 
downstream mechanisms of resistance (e.g., mutational activation of MEK) or to 
those that reduce ERK dependency (e.g., increased PI3K-AKT-mTOR activity). 
MEK Inhibitors 
 
 Currently, there is one FDA-approved MEK1/2 inhibitor for the  treatment of 
BRAF-mutant melanoma, trametinib, and at least 11 other agents in clinical trial 
evaluation (Table 1).  Trametinib and the majority of MEK drugs are allosteric non-
ATP-competitive inhibitors and, consequently, exhibit greater target selectivity than 
ATP-competitive protein kinase inhibitors.  These drugs work by blocking the ability 
of activated MEK to phosphorylate and activate ERK.  In preclinical studies, MEK 
inhibitors that were effective in BRAF-mutant cancer cell lines were not effective in a 
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majority of KRAS- or NRAS-mutant tumor lines[44-46].  Consistent with this, clinical 
trials showed limited to no response of RAS-mutant NSCLC patients to these drugs 
[47,48]. Phase II trials failed to show an advantage of combining trametinib with 
gemcitabine in KRAS-mutant pancreatic cancer[49]. In contrast, the MEK inhibitor 
selumetinib plus docetaxel showed increased overall survival (9.4 months) 
compared with docetaxel alone (5.2 months) in Phase II trials for KRAS-mutant lung 
cancer patients[50,51]. Mutation-selective trends were seen, in that patients with G12V 
mutation-positive cancers responded better than others[50,51].  Other clinical Phase II 
studies have shown that trametinib induces similar progression-free survival and 
response rates as docetaxel in patients with KRAS-mutant- positive NSCLC [52]. 
MEK162 also showed limited activity in NRAS-mutant melanomas[53], where a partial 
response was seen in 20% of NRAS-mutant patients, although the response was 
transient, with rapid onset of resistance. Collectively, the clinical data suggest that 
combination therapies will likely be warranted. 
 Like RAF inhibitors, MEK inhibitors are also limited by mechanisms of drug 
resistance that typically involve the loss of multiple ERK-driven negative feedback 
loops that normally modulate flux through the cascade (Figure 1-5).  Further, while 
initial treatment with MEK inhibitors effectively blocks ERK activation, kinome 
reprogramming (sometimes described as the rewiring of kinase signaling networks) 
drives a rebound in ERK activity within 24 h[54].  Acute inhibition of ERK impairs its 
ability to regulate stability of the MYC oncoprotein[54,55], resulting in loss of RTK 
suppression by this nuclear transcription factor.  Upregulation of RTK expression 
and signaling then overcomes MEK inhibitor activity (Figure 1-6). 
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Two novel MEK inhibitors have distinct mechanisms of action that reduce 
their vulnerability to the loss of ERK-dependent negative feedback loops, and 
consequently may be more effective against RAS-mutant tumors. The clinical 
candidate GDC-0623 stabilizes the RAF-MEK complex in cells, preventing the 
activation of MEK by RAF[44,45]. GDC-0623 showed greater efficacy than 
conventional MEK inhibitors in KRAS-mutant cancer cells. Similarly, the clinical 
candidate RO5126766 forms a stable RAF-MEK-drug complex in cells, preventing 
both MEK and ERK phosphorylation[44,56,45,57,58].  However, these inhibitors remain 
susceptible to resistance mechanisms at the levels of MEK and ERK, as well as 
non-ERK mechanisms. 
ERK Inhibitors 
 
Until recently, it was assumed that RAF and/or MEK inhibitors would be 
sufficient to inhibit ERK1/2 activity and that there would be no additional benefit of 
directly blocking ERK. Thus, development of ERK inhibitors lagged behind RAF and 
MEK drugs. However, because the majority of resistance mechanisms to RAF and 
MEK drugs results in reactivation of ERK1/2, blocking ERK1/2 directly may 
overcome the current limitations of RAF or MEK inhibitors.  Furthermore, although 
reactivation of ERK alone can overcome the loss of MEK function, it is likely that no 
single ERK substrate will be capable of restoring loss of ERK function.  Hence, the 
mechanisms of resistance to ERK inhibitors will likely be both diverse and distinct 
from those of resistance to MEK inhibitors.  
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To date, two potent and selective cell-active preclinical ERK inhibitors have 
been described in the literature: VTX-11e and SCH772984, an analog of the orally 
available clinical candidate MK-8353/SCH900353 (Table 1)[59,60].  VTX-11e is a type 
I ATP-competitive inhibitor, whereas SCH772984 has a dual mechanism of action, 
causing the allosteric inhibition of MEK1/2 binding and ERK phosphorylation and 
also the ATP-competitive inhibition of ERK phosphorylation of its substrates. 
SCH772984 binding adjacent to the ATP binding pocket induces formation of a new 
allosteric pocket that then optimally accommodates the inhibitor[61].  Although VTX-
11e and SCH772984 exhibit different interactions with ERK and distinct mechanisms 
of ERK inhibition[61], both inhibitors exhibit a slow off-rate[61,62], a property that 
prolongs their cellular inhibitory activities. 
In in vitro studies, SCH772984 inhibited cellular proliferation in a subset of 
121 RAS- (49%) or BRAF- (88%) mutant cancer cell lines[60].  Further, the majority 
(11 of 14) NRAS-mutant melanoma cell lines were sensitive to SCH772984 but not 
to vemurafenib [63]. Four ERK1/2 inhibitors are currently undergoing Phase I or I/II 
clinical evaluation (Table 1). GDC-0994[64] and BVD-523 (ulixertinib)[65] have shown 
potency in RAS-mutant cancer cells.  In a Phase I dose escalation in patients with 
advanced solid tumors, BVD-523 achieved ERK inhibition and showed manageable 
tolerability, with adverse events most commonly including diarrhea, nausea, vomiting 
or constipation[66].  Ongoing trials will demonstrate whether sufficient inhibition can 
be achieved for therapeutic benefit. 
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Vertical inhibition of the RAF-MEK-ERK cascade 
 
 Current evidence indicates that inhibition of RAF or MEK alone is not 
sufficient for prolonged arrest of RAS-mutant cancers. Furthermore, the emergence 
of tumor cell resistance and normal tissue toxicity due to blockade of the critical 
RAF-MEK-ERK cascade are anticipated to pose additional limitations.  Instead, 
combination approaches will be needed to effectively 1) overcome bypass of 
inhibitor action that drive ERK reactivation, 2) block ERK-independent mechanisms 
that overcome cancer cell addiction to ERK, and 3) concurrently block other RAS 
effector pathways important for cancer growth. Which combined therapies may 
provide the answer? 
The restricted number of substrates of RAF and MEK led to the earlier 
perception that the RAF-MEK-ERK kinase cascade was a simple linear 
unidirectional pathway. However, there is now greater appreciation that there are 
multiple input and output signals at different levels and that ERK activation 
stimulates feedback inhibitory mechanisms to reduce flux through the pathway. 
Consequently, concurrent inhibition of the pathway at multiple levels may induce a 
more effective inhibition of ERK, .In fact, the combination of the BRAF inhibitor 
dabrafenib with the MEK inhibitor trametinib enhanced progression-free survival and 
reduced toxicity as compared to dabrafenib alone in BRAF-mutant melanoma[67-69], 
leading to FDA approval of this combination for these tumors.  Also, in KRAS-mutant 
tumor cells, unbiased shRNA screening showed that genetic ablation of CRAF 
enhanced MEK inhibitor response[44,70,45].  And the combination of a pan-RAF 
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inhibitor (PRi, Amgen Compd A) with trametinib showed a synergistic effect on the 
growth inhibition of NRAS-mutant melanoma cells[71].   
Although combining RAF and MEK inhibitors has shown greater clinical 
efficacy in BRAF-mutant melanoma cancers than either drug alone, reactivation of 
ERK signaling limits the long-term effectiveness of this combination[72,29].  BRAF-
mutant melanomas acquired resistance to combined dabrafenib and trametinib 
treatment by several alterations (BRAF amplification and NRAS or MEK1/2 
mutational activation) that ultimately led to ERK reactivation.  These results 
prompted studies to evaluate if blockade of ERK can overcome resistance to RAF 
and/or MEK inhibition. Data from multiple studies in different cancers has shown that 
this is the case.  In fact, resistance of a BRAF-mutant melanoma cell line to 
concurrent vemurafenib and trametinib treatment was overcome by the ERK-
selective inhibitor SCH772984[60].  Similarly, a BRAF-mutant melanoma cell line 
resistant to a RAF/MEK inhibitor combination due to MEK2 mutation remained 
sensitive to the preclinical ERK inhibitor VTX-11e[72,29]. Further, KRAS-mutant tumor 
cell lines resistant to MEK inhibitor (PD0325901) retained sensitivity to VTX-11e[73].  
Co-treatment with VTX-11e enhanced the growth inhibitory activity of selumetinib 
and trametinib by preventing RAF-dependent rebound of flux through the RAF-MEK-
ERK cascade, and caused apoptosis in NRAS-mutant melanoma cells[74].  Finally, 
SCH772984 was also effective in both NRAS- and BRAF-mutant melanoma cell 
lines, and synergized with vemurafenib in BRAF-mutant lines[63].   Thus, ERK 
inhibition in combination with RAF and/or MEK inhibition may be a superior 
therapeutic strategy to inhibition of any single step alone. 
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Despite these promising findings, ERK inhibitors will also likely be limited by 
both de novo and acquired mechanisms of resistance.  A recent study found that 
experimentally induced mutations in ERK1 and ERK2 conferred resistance to VTX-
11e or SCH772984 treatment[15].  However, the fact that these mutations did not 
confer cross-resistance to RAF or MEK inhibitors supports the value of combining 
ERK inhibitors with RAF or MEK inhibitors. 
ERK substrates 
 
ERK1/2 kinases undergo nuclear/cytoplasmic shuttling and translocate to the 
nucleus upon phosphorylation.  ERK subcellular localization is further regulated by 
dimerization and by interaction with scaffold proteins (e.g., kinase suppressor of Ras 
(KSR)), and this localization in turn regulates ERK selectivity towards its substrates 
[75].  Unlike the restricted substrate profile for RAF and MEK, >200 nuclear and 
cytoplasmic ERK substrates have been identified[76,77].  The specific ERK substrates 
that are critical for ERK-dependent cancer growth remain poorly understood, with 
opposing conclusions reached regarding whether nuclear or cytoplasmic substrates, 
or both, are critical for cancer progression  For example, the multi-functional protein 
PEA-15 binds and sequesters ERK in the cytoplasm, and genetic ablation of PEA-15 
increased ERK nuclear localization and promoted cellular proliferation[78].  In a study 
where whole-body KrasG12D activation was induced, tumorigenesis was driven in a 
subset of mouse tissues that was associated with nuclear accumulation of activated 
ERK and activation of nuclear substrates. In contrast, nonresponsive tissue was 
associated with cytoplasmic ERK[79].  Further, the nuclear import protein importin7 
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facilitates ERK nuclear translocation by recognition of the phosphorylated nuclear 
translocation signal (NTS), and an NTS-derived phosphomimetic peptide that blocks 
nuclear translocation of ERK impairs the growth of RAS- or BRAF-mutant tumor cell 
lines[80].  Because many nuclear ERK substrates are associated with cell 
proliferation whereas ERK negative feedback targets are cytosolic (Figure 1-5), the 
selective inhibition of phosphorylation of ERK nuclear substrates might favor 
inhibition of tumor growth. Among the multitude of nuclear transcription factors that 
are ERK substrates, MYC is likely a critical mediator of ERK effects in RAS-mutant 
cancers. Substantial evidence shows that MYC is essential for RAS-driven cancer 
initiation and growth[81-83].  MYC is a critical driver of KrasG12D-dependent up-
regulation of genes that support the increased glycolytic and metabolic needs of 
pancreatic tumors[84], and ERK phosphorylation of MYC prevents MYC protein 
degradation[85].  
In contrast, the therapeutic response to vemurafenib correlated with reduction 
in cytoplasmic rather than nuclear ERK phosphorylation, arguing for a critical role of 
cytoplasmic ERK substrates[28]. This finding is consistent with observations that ERK 
dimerization is essential for the activation of cytoplasmic but not nuclear substrates, 
and that preventing ERK dimerization impaired the tumorigenic growth of RAS-
mutant cancer cell lines[86].  Recent efforts have demonstrated that 
pharmacologically targeting ERK dimerization can lead to a significant reduction in 
RAS-driven tumor growth by potently inhibiting phosphorylation of ERK cytoplasmic 
substrates.  The ERK dimerization inhibitor DEL-22379 reduced tumor growth in 
mutant KRAS xenograft models and was able to overcome upstream resistance 
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mechanisms, including NRAS overexpression and MEK mutation[87]. Among ERK1/2 
cytoplasmic substrates that drive tumorigenesis are the RSK serine/threonine 
kinases.  RSKs are major effectors of the ERK1/2 kinases and have been identified 
as drivers of motility and invasiveness in cancer, as regulators of mTOR in BRAF-
mutant cancers, and as drivers of chemoresistance[88,89].  Clearly, further work is 
needed to fully understand the importance of the diverse spectrum of ERK 
substrates in RAS-driven cancers. 
Combined inhibition of RAF-MEK-ERK and PI3K-AKT-mTOR signaling 
 
 In addition to ERK reactivation downstream of RAF and MEK inhibitors, 
increased activation of the PI3K-AKT-mTOR pathway has also been observed. This 
can occur by increased RTK signaling[90] and therefore concurrent treatment with 
RTK inhibitors may enhance inhibition of RAF-MEK-ERK signaling.  Combining 
inhibitors of the PI3K-AKT-mTOR pathway with MEK inhibitors effectively inhibited 
NRAS-mutant melanoma growth both in vitro and in vivo[91].  In KRAS-mutant 
pancreatic cancer, the dual PI3K-mTOR inhibitor BEZ235 enhanced MEK/ERK 
signaling, which could be reversed by the addition of a MEK inhibitor, leading to 
enhanced growth suppression compared to targeting either pathway alone[92].  
Similarly, combination of the PI3K inhibitor GDC-0973 with the MEK inhibitor GDC-
0941 was able to confer a greater survival advantage in a KrasG12D-driven mouse 
model of pancreatic cancer than either inhibitor alone[93].  Pre-clinical findings with 
combined PI3K-AKT-mTOR and RAF-MEK-ERK inhibition have been followed by 
early clinical trials in a small series of KRAS-driven cancers including NSCLC, 
colorectal, pancreatic and ovarian[94,95]. Occasional partial responses were noted, 
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particularly in ovarian cancers, although normal tissue toxicity remains a 
concern[94,95].   
The RAC effector pathway 
 
 Many additional effector pathways can contribute to the tumorigenic potential 
of RAS , including the T-cell Tiam1-RAC1 pathway.  RAC1 is a GTPase which 
cycles between and active GTP bound state and an inactive GDP bound state, in a 
similar fashion to wilde-type RAS.  RAC1 can be activated by many upstream 
guanine nucleotide exchange factors (GEFs), including Tiam1, which is directly 
activated by RAS[96,97].  In a RAS(V12)-driven model of skin cancer, Tiam1 deficient 
mice were found to be resistant to the formation of tumors, emphasizing an essential 
role for RAC1 in RAS signaling[98].  Additional GEFs can also interact with and 
activate RAC1 in cancers, including VAVs, ECT2, and PREXs[99].  The RAC 
pathway, and its downstream substrates, p21 activated kinases (PAKs), also hold 
promise as an anti-cancer therapeutic strategy in RAS-driven cancers[100]. 
 The RAC1 pathway has been found to play an essential role in melanoma 
progression downstream of either mutant NRAS or BRAF as well as representing a 
potential resistance mechanism to RAF-MEK-ERK cascade inhibition.  RAC1 
mutation can accelerate melanoma development and a fast cycling mutant of RAC1 
(P29S) was found to confer resistance to the RAF-inhibitor vemurafenib[31,101,32].   
The RacGEF PREX2 was also found to be frequently mutated in melanoma and 
altered RAC signaling[102,103].  Work from our lab has shown a role for the highly 
related protein PREX1 in regulating metastasis in an Nras-mutant mouse model and 
identified PREX1 as a gene potentially regulated downstream of the RAF-MEK-ERK 
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cascade[104,105].  My studies described in Chapter 2 focused on the role of ERK in 
regulating PREX1 in both NRAS- and  BRAF-mutant melanomas. 
MAPK cascades, more than just RAF-MEK-ERK 
 
 While the RAF-MEK-ERK cascade is the best characterized effector 
downstream of RAS, it is just one of many MAPK cascades in mammalian cells.  All 
MAPK cascades follow a three tiered structure of MAP kinase kinase kinase 
(MAP3K), MAP kinase kinase (MAP2K) and MAPK and can be grouped into three 
families, ERK, Jun amino-terminal kinases (JNKs), and p38 kinases[16].  Collectively, 
the JNK and p38 MAPK cascades are known as the stress activated MAPKs and are 
activated in response to both intracellular and extracellular stimuli, such as UV 
radiation, osmotic shock, RTK activation, and response to chemotherapy[106]. 
 My studies described in Chapter 3 focused on the p38 MAPK cascade as a 
potential mechanism of resistance to ERK inhibition in KRAS-mutant PDAC.  The 
ERK and p38 MAPK cascades regulate diverse cellular processes, with p38 and 
ERK representing the terminal node of their respective MAPK cascades[107,108]. In 
cancer, p38 can play both a tumor promoting role or a tumor suppressing role, 
depending on the cellular and tumor type context[109]. The p38 MAPK cascade can 
also play a role in response to both chemotherapy and targeted therapy in cancer. In 
KRAS-mutant PDAC, the p38 MAPK cascade can paradoxically play both a tumor 
suppressive role while also acting in a tumor promoting role by contributing to 
resistance to the nucleoside analog gemcitabine[110,111].  In Chapter 3, I explore the 
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role of p38 in conferring resistance to ERK inhibition and demonstrate synergy 
between concurrent p38 and ERK inhibition in PDAC. 
Concluding Remarks  
 
 While direct inhibitors of RAS remain the ideal strategy for clinically active 
anti-RAS drug discovery, inhibitors of the RAF-MEK-ERK cascade arguably hold the 
greatest promise for the immediate future.  With earlier perceptions that this protein 
kinase cascade operated as a simple linear unidirectional pathway, initial efforts 
centered on MEK inhibitors, and subsequently on RAF inhibitors, to block ERK 
activation.  As the development of RAF and MEK inhibitors progressed, it became 
painfully apparent that cancer cells can dynamically rewire their signaling networks 
to restore ERK activity and override the actions of inhibitors that act upstream of 
ERK. These revelations have led the field to consider ERK itself as perhaps the 
“best” node for effective disruption of ERK signaling. 
As ERK inhibitors transit through clinical evaluation, new issues will likely 
arise that will challenge the usefulness of ERK inhibitors for cancer treatment.  While 
ERK is clearly a key driver of cancer growth, it is also an essential component in 
normal cell physiology.  Therefore, achieving a therapeutic index and minimizing 
normal tissue toxicity will be one challenge.  Another will be acquired mechanisms of 
cancer cell resistance to ERK inhibition.  However, unlike RAF or MEK, ERK action 
cannot be attributed to a single substrate.  Thus, mechanisms of resistance to ERK 
inhibitors will likely be distinct from those that overcome the actions of RAF or MEK 
inhibitors, and likely more complex and varied as well. Defining combination 
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approaches with ERK inhibitors that might overcome cancer cell resistance and 
normal cell toxicity will be key challenges for the development of ERK inhibitors.  
Innovative chemical library or genetic functional screens will provide helpful 
unbiased functional strategies to address this need[112,113]. 
Other strategies beyond protein kinase inhibitors to block growth dependent 
on RAF-MEK-ERK signaling, for example inhibitors of RAF or ERK dimerization, are 
also being pursued.  Defining the key ERK substrates critical for ERK-dependent 
cancer growth remains to be fully elucidated and may provide additional targets for 
effective blockade of ERK activation in cancer.  Additional pathways, such as RAC1 
and the p38 MAPK cascade can also be utilized as therapeutic strategies to target 
RAS dependency and overcome resistance to RAF-MEK-ERK cascade inhibitors, 
including ERK inhibitors. 
Finally, even if direct inhibitors of RAS can be developed, given experimental 
evidence that cancers can overcome their addiction to mutant RAS, defining the 
mechanisms by which they accomplish this will also be important.  Nevertheless, 
despite the considerable uncertainty ahead (see Outstanding Questions), there is 
renewed albeit cautious optimism that an effective anti-RAS strategy may finally be 
at hand.  
  My dissertation studies focused on two aspects of ERK MAPK signaling as a 
potential anti-RAS strategy: ERK regulation of the RacGEF PREX1 in NRAS- and 
BRAF-mutant melanoma, described in Chapter 2, and synergy between p38 and 
ERK inhibitors in KRAS-mutant PDAC, described in Chapter 3. 
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Figure 1-1 History of anti-RAS drug discovery 
Summary of key representative events in the search for the still-elusive anti-RAS drugs.  
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Figure 1-2. The RAS proteins   (a) RAS oncogenes (HRAS, NRAS and KRas) comprise 
the most frequently mutated gene family in cancer[2,3].  Overall, RAS mutations are found in 
~25% of human cancers (COSMIC v73). The mutation frequency is not uniform, with 
frequencies highest in three of the four most deadly cancers in the United States- lung 
(30%), colorectal (50%) and pancreatic (95%) carcinomas.  The frequency of mutation of 
each RAS isoform is also not uniform, with 85% of all RAS mutations found in KRAS, 
followed by NRAS (11%), whereas HRAS is infrequently mutated (4%).  (b) The three RAS 
genes encode four highly related proteins of 188-189 amino acids (82-90% sequence 
identity): HRAS, KRAS4A, KRAS4B and NRAS.  RAS proteins are comprised of a highly 
conserved N-terminal G domain (90% amino acid sequence identity) involved in GTP 
binding and hydrolysis and a C-terminal membrane-targeting hypervariable (HV) sequence. 
Underlined C, cysteine of the CAAX motif (highlighted in yellow, the site for farnesylation; 
see Figure 1). Underlined K, lysine(s) comprising the polybasic domain.  Boxed C, site of 
palmitoylation. Circled S, site of phosphorylation by PKC.  (c) RAS proteins function as 
GDP-GTP regulated binary on-off switches.  In normal quiescent cells, RAS is 
predominantly GDP-bound and inactive. Growth factors activate RAS-selective guanine 
nucleotide exchange factors (RASGEFs; e.g., SOS1) to promote nucleotide exchange and 
formation of active RAS-GTP. Once in the active, GTP-bound conformation, RAS can bind 
to a variety of effector proteins that contain Ras Binding or RAS Association Domains 
(RBDs/RAs), in order to transmit its downstream signals.  RAS-selective GTPase 
accelerating proteins (RASGAPs; e.g., NF1, neurofibromin) then promote GTP hydrolysis to 
return RAS to its GDP-bound resting state.  Mutated RAS genes in cancer harbor missense 
mutations primarily at three hotspots (G12, G13 and Q61, marked by asterisks); they 
encode mutant RAS proteins that are GAP-insensitive and are persistently GTP-bound and 
active.   
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Figure 1-3.  Pharmacological strategies to inhibit aberrant RAS function. RAS proteins 
(center, structure of KRAS4B) must associate with membranes (top) to be biologically 
active.  Once activated, RAS proteins signal to effector cascades that ultimately alter gene 
transcription (bottom).  Shown are one direct and four indirect strategies (1-4) to inhibit the 
function of RAS in cancer.  See text for details. 
 
 
 
 
 
 
 
 
 
 25 
 
 
Figure 1-4. Components of the RAF-MEK-ERK MAPK cascade.  The RAF-MEK-ERK 
mitogen-activated protein kinase (MAPK) cascade comprises three sequentially activated 
protein kinase events: RAF (MAPKKK)→ MEK (MAPKK)→ ERK (MAPK). There are three 
highly identical human RAF MAPKKK isoforms (ARAF, BRAF, and CRAF), and RAS-
mediated homo- or hetero-dimerization of RAF is essential for their full activation[114].  
Binding of activated RAS-GTP to the N-terminal RAS-binding domain (RBD) of RAF relieves 
the N-terminal auto-inhibition of the C-terminal RAF kinase domain and promotes 
association of the normally cytosolic RAF protein with the plasma membrane, where 
complex subsequent activation events lead to activation of RAF kinase activity. A still 
incompletely understood complex set of both negative (red) and positive (green) 
phosphorylation events regulate RAF catalytic activity[115] (representative sites shown).  In 
the inactive configuration, a 14-3-3 dimer binds to conserved phosphorylation sites in N- and 
C-terminal residues flanking the kinase domain (ARAF, pS214 and pS576; BRAF, pS365 
and p729; CRAF, pS259 and pS621).  Protein kinase A and other kinases can 
phosphorylate these sites.  Phosphorylation events that promote kinase activation occur at 
residues including S338 and Y341 in CRAF (S299 and Y302; ARAF).  However, the 
analogous positions in BRAF are either constitutively phosphorylated (S446) or encode a 
phosphomimetic residue (D449), explaining why BRAF but not ARAF or RAF can be 
rendered constitutively activated by a single missense mutation in cancer (V600E).  Each 
activated RAF isoform phosphorylates and activates the highly related MEK1 and MEK2 
dual-specificity MAPKKs. Activated MEK1/2 phosphorylate and activate the highly related 
ERK1 and ERK2 serine/threonine kinases.  Total protein and kinase domain sequence 
identities are indicated (%/%) as determined by CLUSTALW multiple sequence alignment.  
In stark contrast to the limited substrates of A/B/CRAF and MEK1/2, >200 cytoplasmic and 
nuclear substrates of ERK1/2 have been described[76]. 
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Figure 1-5. Regulatory mechanisms of ERK negative feedback regulation.  ERK 
phosphorylation of CRAF disrupts interaction with RAS.  ERK phosphorylation of BRAF 
disrupts dimerization and interaction with RAS.  ERK phosphorylation of MEK1 promotes 
heterodimerization with MEK2.  ERK phosphorylation of SOS1 disrupts interaction with 
GRB2.  ERK phosphorylation of the dual specificity phosphatase DUSP6 regulates its 
protein stability.  ERK-activated transcription factors promote expression of DUSP6[116] and 
the scaffold protein SPRY, with SPRY disrupting SOS1 interaction with GRB2.  ERK 
phosphorylation of T669 in the EGFR juxtamembrane region is important for EGFR 
dimerization and activation[117], promoting activation of RAS[118] and PI3K[119]. 
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Figure 1-6. Mechanisms of resistance to RAF and MEK inhibitors in RAS-mutant 
cancers.  Second generation RAF inhibitors such as vemurafenib and dabrafenib are 
BRAF-selective and cause paradoxical activation of ERK (panel a).  The inhibitor-blocked 
BRAF forms a heterodimer with active CRAF, and complexes with activated RAS.  MEK 
inhibitors transiently block ERK activation.  Since high ERK activation can be deleterious for 
cell proliferation, ERK activation stimulates negative feedback mechanisms that dampen 
upstream signaling through the pathway (panel b).  Kinome reprogramming results in 
rewiring of the signaling networks to increase flux through non-RAF-MEK-ERK pathways 
such as PI3K-AKT-mTOR.   
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Table 1. RAF-MEK-ERK inhibitors under clinical evaluation 
Agent Other Names Phase
a
 Targets Mechanism and properties
e
 
RAF 
BGB-283  Phase I
b
 RAF, EGFR Dual RAF dimer and EGFR inhibitor
b
 
BMS-908662 XL281 Phase I/ II
c
 RAF ATP-competitive, pan-RAF 
Dabrafenib GSK2118436 
Approved for BRAF V600E 
melanoma 
RAF 
Type I ATP-competitive, BRAF-
selective 
Encorafenib LGX818 Phase II RAF ATP-competitive, BRAF-selective 
HM95573  Phase I RAF Pan-RAF 
LY3009120  Phase I RAF ATP-competitive, “paradox breaker” 
MLN2480 BIIB-024 Phase I RAF Pan-RAF 
RAF265 CHIR-265 Phase I/ II
c
 RAF, VEGFR ATP-competitive, multi-kinase 
Regorafenib BAY 73-4506 
Approved for metastatic colorectal 
cancer and advanced 
gastrointestinal stroma tumors 
RAF, KIT, 
VEGFR 
Type II ATP-competitive, multi-
kinase 
Sorafenib BAY 43-9006 
Approved for unresectable 
hepatocellular carcinoma, advanced 
renal cell carcinoma and thyroid 
cancer 
VEGFR2, 
PDGFR, KIT, 
FLT3, CRAF 
Type II ATP-competitive, multi-
kinase 
Vemurafenib 
PLX4032, RG7204, 
RO5185426 
Approved for BRAF V600E 
melanoma 
 
Type I ATP-competitive, BRAF-
selective 
MEK 
ARRY-300  Phase I
c
 MEK1/2 
Type III allosteric, non-ATP-
competitive; analog of MEK162 
AS703988 MSC2015103B Phase I
c
 MEK1/2 
Type III allosteric, non-ATP-
competitive 
AZD8330 
ARRY-424704, 
ARRY-704 
Phase I
c
 MEK1/2 
Type III allosteric, non-ATP-
competitive 
Binimetinib 
ARRY-438162, 
ARRY-162, 
MEK162 
Phase II MEK1/2 
Type III allosteric, non-ATP-
competitive 
Cobimetinib 
XL-518, 
GDC-0973, 
RG7421 
Phase III MEK1 
Non-ATP competitive, 100-fold 
selectively for MEK1 over MEK2 
E6201  ER 806201 Phase I/II 
MEK1, 
MEKK1 
FLT3 
Synthetic, fungal metabolite 
analogue 
GDC-0623 
RG7420, 
G-868 
Phase I
c
 MEK1/2 
Type III allosteric, non-ATP-
competitive; analog of CI-1040; 
stabilizes a RAF-MEK complex 
PD-0325901   Phase II MEK1/2 
Type III allosteric, non-ATP-
competitive 
Pimasertib 
AS703026,  
SAR245509, 
EMD 1036239, 
MSC1936369B 
Phase II MEK1/2 
Type III allosteric, non-ATP-
competitive 
Refametinib 
RDEA119, 
BAY86-9766 
Phase II MEK1/2 Allosteric, non-ATP-competitive 
RO4987655 
CH4987655, 
RG7167 
Phase I
c
 MEK1/2 Allosteric, non-ATP-competitive 
RO5126766 
CH5126766, 
RG7304 
Phase I
c
 Raf, MEK1/2 
Type III allosteric, non-ATP-
competitive; binds to MEK1/2, forms 
a stable Raf-MEK-RO5126766 
complex, preventing both MEK and 
ERK phosphorylation 
Selumetinib 
AZD6244, 
ARRY-142886 
Phase III MEK1/2 
Type III allosteric, non-ATP-
competitive 
TAK733  Phase I
c
 MEK1/2 
Type III allosteric, non-ATP-
competitive 
Trametinib 
GSK1120212, 
JTP-74057 
Approved for BRAF V600E 
melanoma 
MEK1/2 
Type III allosteric, non-ATP-
competitive 
WX-554  Phase I/II
d
   
ERK 
CC-90003  Phase I ERK1/2  
GDC-0994 RG7842 Phase I ERK1/2 ATP-competitive 
MK-8353 SCH900353 Phase I
d
 ERK1/2 Allosteric and ATP-competitive 
Ulixertinib  BVD-523 Phase I/II ERK1/2 ATP-competitive 
a
Compiled from ClinicalTrials.gov 
bhttp://www.beigene.com/ 
cCompleted 
dTerminated 
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eATP-competitive inhibitors are broadly classified as type I or II, that target the active “in” or 
inactive “out” conformation of the ATP/Mg2+-coordinating three amino acid DFG motif, highly 
conserved among most protein kinases and located N-terminal to the activation loop. Type 
III inhibitors bind to a hydrophobic pocket directly adjacent to the ATP-binding site. 
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Chapter II: ERK/MAPK SIGNALING DRIVES OVEREXPRESSION  
OF THE RAC-GEF, PREX1, IN BRAF- AND NRAS-MUTANT MELANOMA2 
 
 
OVERVIEW 
 
Recently we identified that PREX1 overexpression is critical for metastatic but 
not tumorigenic growth in a mouse model of NRAS-driven melanoma.  In addition, a 
PREX1 gene signature correlated with and was dependent on ERK mitogen-
activated protein kinase (MAPK) activation in human melanoma cell lines.  In the 
current study, the underlying mechanism of PREX1 overexpression in human 
melanoma was assessed.  PREX1 protein levels were increased in melanoma tumor 
tissues and cell lines compared with benign nevi and normal melanocytes, 
respectively.  Suppression of PREX1 by siRNA impaired invasion but not 
proliferation in vitro.  PREX1-dependent invasion was attributable to PREX1-
mediated activation of the small GTPase RAC1 but not the related small GTPase 
CDC42.  Pharmacologic inhibition of ERK signaling reduced PREX1 gene 
transcription and additionally regulated PREX1 protein stability.  This ERK-
dependent upregulation of PREX1 in melanoma, due to both increased gene 
transcription and protein stability, contrasts with the mechanisms identified in breast 
                                                          
2
 Adapted from previously published work.  Authors are Meagan B. Ryan, Katherine H. Pedone, 
Alexander J. Finn, Nancy E. Thomas, Channing J. Der, and Adrienne D. Cox.  All Figures except 
Figures 2-1, 2-7 and 2-8 represent the work of Meagan B. Ryan. 
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and prostate cancers, where PREX1 overexpression was driven by gene 
amplification and HDAC-mediated gene transcription, respectively.  Thus, although 
PREX1 expression is aberrantly upregulated and regulates RAC1 activity and 
invasion in these three different tumor types, the mechanisms of its upregulation are 
distinct and context-dependent.   
INTRODUCTION 
Driver roles in cancer have been identified for several members of the Dbl 
family of Rho guanine nucleotide exchange factors (RhoGEFs), most prominently 
ECT2, TIAM1, VAV1/2/3 and PREX1/2 [120,99].  Increased expression and activation 
of these RhoGEFs result in enhanced activity of their Rho family small GTPase 
substrates in a context-dependent manner.  For example, we recently identified 
overexpression of ECT2 protein in ovarian cancer, mediated by gene amplification, 
that resulted in activation of RHOA in the cytosol and RAC1 in the nucleus[121].  The 
critical importance of RAC1 in cancer cell migration and invasion[122] has further 
focused attention on the mechanisms regulating activators of RAC1, such as the Dbl 
family of RhoGEFs. 
The highly related Dbl RhoGEFs PREX1 and PREX2 (56% overall amino acid 
identity), which are GEFs for RAC1 and other Rho family small GTPases such as 
CDC42[123], have been implicated as cancer drivers in several tumor types. The first 
cancer-driving role for PREX1 was described in prostate cancer[124], where limited 
analyses of tumor tissue revealed elevated levels of PREX1 protein.  PREX1 was 
also elevated in metastatic but not primary prostate tumor cell lines. Suppression of 
PREX1 by RNA interference in PC-3 human prostate cancer cells decreased the 
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levels of activated RAC and impaired tumor cell migration and invasion in vitro.  
Conversely, ectopic expression of PREX1 stimulated RAC activation, and promoted 
metastatic but not primary tumor growth of CWR22Rv1 prostate tumor cells.  A 
follow-up study identified a histone deacetylase (HDAC)-mediated increase in 
PREX1 gene transcription as a basis for the increased levels of PREX1 protein in 
prostate cancer[125].   
PREX1 overexpression was also identified in estrogen receptor-positive 
luminal and HER2-positive breast cancers[126-128].  PREX1 protein was detected in 
~60% of breast tumors but not in normal breast tissue.  PREX1 is located in a 
chromosomal region frequently amplified in breast cancers and PREX1 gene 
amplification was detected in breast cancer cell lines, supporting gene amplification 
as a mechanism for PREX1 protein overexpression in these tumor types. Silencing 
of PREX1 expression by RNA interference reduced HER2-stimulated activation of 
RAC1, and impaired tumor cell motility and invasion in vitro and tumorigenic growth 
in vivo[126-128].  
A role in cancer for the related RhoGEF PREX2 has also been identified, but 
not by overexpression.  Instead, missense mutations in PREX2 have been identified 
in 25% of malignant melanomas[102].  Although no clear mutational hotspots have 
been seen in melanomas, experimental studies support a gain-of-function 
consequence of these mutations[102,103].  PREX2 missense mutations have also been 
found in 38% of cutaneous squamous cell carcinomas[129] and 17% of stomach 
adenocarcinomas[130]. To date, a similar level of activating missense mutations in 
PREX1 in cancer has not been reported. However, the occurrence of activating 
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missense mutations (e.g., P29S) in the PREX1 substrate, RAC1, in ~11% of 
melanomas[31,131] is also consistent with a driver role for overexpressed PREX1 in 
this disease.   
Our previous studies revealed overexpression of PREX1 protein in melanoma 
cell lines and tumor tissue[105].  Further, in a mouse model of melanoma, we 
determined that Prex1-deficient mice were impaired in forming tumor metastases but 
not primary tumors.  Here, extending our mouse model studies, we demonstrate that 
PREX1 protein is increased in human melanoma tumor tissue and that PREX1 is 
required for human melanoma cell invasion but not proliferation. 
In a separate earlier study, we also identified PREX1 as a gene upregulated 
by the ERK mitogen-activated protein kinase (MAPK) in melanoma[104].  The RAF-
MEK-ERK protein kinase cascade is aberrantly activated in up to 80% of melanomas 
through BRAF or NRAS mutation, and serves as a critical therapeutic target in this 
disease[15,132-134].  These observations supported the possibility that PREX1 protein 
overexpression in melanoma is driven by ERK activation.  Additionally, since PREX1 
has a demonstrated driver role in other cancers, PREX1 overexpression may be a 
key driver of ERK-dependent melanoma growth.  In the present study, we 
determined that PREX1 protein overexpression is blocked by pharmacologic 
inhibitors of RAF-MEK-ERK signaling, and that ERK regulates not only PREX1 gene 
transcription but also PREX1 protein stability. Thus, there are significant cancer 
type-distinct mechanisms that drive PREX1 overexpression in cancer.   
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MATERIALS AND METHODS 
 
 
Human melanoma tissue and immunohistochemistry (IHC)  
Following institutional review board approval, primary and metastatic 
melanomas were retrieved from a series of patients treated at UNC Healthcare.  
Immunohistochemical staining was performed in the UNC Department of 
Dermatology Dermatopathology Laboratory as we have recently described[135]. 
Briefly, freshly cut 4-µm thick sections of formalin-fixed and paraffin-embedded 
melanoma tissue blocks were stained using the fully automated Leica Bond III 
system. Sections were pretreated using an onboard heat-induced epitope retrieval in 
EDTA buffer. Following incubation with PREX1 antibody (6F12; provided by Marcus 
Thelen, IRB, Switzerland), chromogenic detection was performed using the Leica 
Refined Red polymer detection system (Leica Microsystems). Some sections were 
also counterstained with hematoxylin and eosin (H&E). PREX1 antibody staining 
intensity was scored in a blinded manner by a pathologist (AJ Finn) as high, 
medium, low or none. 
Tissue culture 
Cutaneous melanoma, breast cancer and prostate cancer cell lines were 
obtained from ATCC.  Cells were maintained in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS), and were not cultured 
for longer than 6 months after receipt from cell banks. 
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siRNA transfection, proliferation, and invasion assays 
For siRNA knockdown, A375, WM2664, SK-MEL-119 and Mel224 cells were 
plated in 6-well plates.  Cells were transfected with 10 nM siRNA against PREX1 
(Thermo Fisher s33364, s33365, s33366; PREX1 #1, #2, #3, respectively), RAC1 
(Thermo Fisher s11711, s11712, s11713; RAC1 #1, #2, #3, respectively) or 
mismatch control (Dharmacon #D-001210-05), using Lipofectamine RNAimax (Life 
Technologies).   Cells were serum-starved overnight for 18 h and then seeded for 
invasion assays after 48 h of siRNA knockdown.  For the proliferation assay, cells 
were seeded at 2-3 x 103 cells/well in 96-well plates and allowed to grow for 72 h 
before incubation for 3 h in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT).  MTT was solubilized in DMSO and the absorbance was read at 
A570.  For the Boyden chamber invasion assay, 1-3 x 104 cells were seeded into the 
upper chamber of Matrigel-coated invasion chambers in duplicate (Corning BioCoat) 
and allowed to invade towards 20% FBS in DMEM for 24 h.  Invasion chambers 
were fixed and stained using a Diff-Quik staining kit (GE).  Invasion chambers were 
imaged using a 10x objective lens on a Nikon TS100 microscope at 5 fields per 
insert, and images were analyzed to calculate invaded cells per field using ImageJ 
software.  For the collagen spheroid invasion assay, we slightly modified a published 
protocol[136,137].  Briefly, 5-10 x 103 cells were seeded in ultra-low attachment round-
bottomed 96-well plates (Corning) for 96 h, a sufficient time for the cells to organize 
into spheroids. Spheroids were then transferred to 48-well plates and embedded in 
collagen (1 mg/ml rat-tail collagen, BD).  Spheroids were imaged at 0 h and after 72 
h of invasion using a 5x objective on a Nikon TS100 microscope.  Total spheroid 
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area was calculated as fold-change in area of 72 h outgrowth versus 0 h spheroid 
area, using ImageJ.  
Pulldown assay to detect GTPase activity 
Levels of active, GTP-bound RAC1 and CDC42 were assessed by an affinity 
pulldown assay as we described previously[138].  Briefly, after 48 h of siRNA-
mediated PREX1 knockdown, whole cell lysates were exposed to GST-PAK-PBD, 
which contains the binding domain of the shared RAC1/CDC42 effector PAK1.  After 
resolving pulldown samples on 15% SDS-PAGE gels and western blotting for RAC1 
(clone 23A9, BD) and CDC42 (BD), levels of each GTP-bound GTPase were 
normalized to both total protein and the vinculin loading control (Sigma) by 
densitometry analysis performed in ImageJ. 
Drug treatment and western blotting 
BRAF-mutant A375 and WM2664 cells were treated with BRAF inhibitor 
vemurafenib (Selleckchem) or ERK inhibitor SCH772984 (Merck, kindly provided by 
Ahmed Samatar), and NRAS-mutant SK-MEL-119 and Mel224 cells were treated 
with MEK inhibitor trametinib (Selleckchem) or SCH772984 for 24 and 48 h before 
samples were collected in RIPA lysis buffer.  For PREX1 protein stability 
experiments, cells were co-treated with cycloheximide (50 µg/ml) and SCH772984 
for a 24 h timecourse before samples were collected in RIPA.  Whole cell lysates 
were resolved on 10% SDS-PAGE gels and western blotting was performed using 
antibodies to phospho-ERK1/2 (Thr202/Tyr204), total ERK1/2, phospho-RSK 
(Ser308), phospho-RSK (Thr359/Ser363), total RSK1/2/3, and c-myc (MYC) (Cell 
Signaling); β-actin and vinculin (Sigma), and PREX1 (6F12)[139].  IRDye800-
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conjugated anti-mouse and anti-rabbit secondary antibodies were from Rockland 
Immunochemicals. 
Quantitative PCR 
Total RNA was isolated using an RNeasy kit (Qiagen) and reverse 
transcription was performed using the High Capacity RNA-to-cDNA kit (Thermo 
Fisher).  Real time quantitative Taqman PCR was performed on the QuantStudio 6 
Flex (Thermo Fisher) with FAM/MGB labeled probes against PREX1 
(Hs00368207_m1, Hs_001031512, Thermo Fisher) and endogenous control 
VIC/TAMRA labeled β-actin (Thermo Fisher).   
Statistical analysis 
Data were analyzed using GraphPad Prism 6 software and statistical 
analyses were performed as indicated in the Figure Legends. 
 
RESULTS 
 
PREX1 overexpression is correlated with elevated ERK activation   
We recently identified overexpression of PREX1 protein in melanomas, 
determined that Prex1 deficiency impaired mouse melanoblast migration in vivo, and 
demonstrated that Prex1 expression is required for metastasis in an Nras-mutant 
genetically engineered mouse model of cutaneous melanoma[105].  Since our 
previous gene array analyses identified PREX1 as an ERK activation-dependent 
gene[104], here we assessed a relationship among BRAF and NRAS mutation status, 
ERK activation and PREX1 protein overexpression in human melanoma.  We first 
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investigated the expression of PREX1 in a panel of human melanoma cell lines that 
did or did not harbor BRAF or NRAS mutations.  The majority of BRAF- (3 of 4) or 
NRAS- (3 of 4) mutant cell lines exhibited substantially higher PREX1 protein 
expression when compared with normal melanocytes or with BRAF/NRAS wild type 
cell lines (Figure 2-1A).  Generally, the level of activated, phosphorylated ERK 
(pERK) correlated with the level of PREX1.  In our analyses, normal melanocytes 
may exhibit low pERK levels[104], or they may also display low PREX1 protein levels 
even in the presence of high pERK levels, as shown here. 
We next utilized immunohistochemistry (IHC) to evaluate PREX1 protein 
expression and pERK levels in melanoma patient tissues. We first compared PREX1 
expression in benign melanocytic nevi (n=35) and human melanoma tumors (n=33) 
(Figure 2-1B).  A range of expression was seen in nevi, with ~75% expressing low-
to-medium levels of PREX1.  Since BRAF and NRAS mutations are found in a high 
percentage of nevi[140,141], it is not surprising to find PREX1 in nevi as well as in 
melanoma tissue.  However, high level PREX1 expression was detected only in 
melanomas (~10%, Figure 2-1B). 
ERK can phosphorylate numerous substrates present in both the nucleus and 
the cytoplasm[76,142], few of which have been firmly linked to specific outcomes of 
ERK-mediated signaling. Melanoma responses to pharmacological inhibitors of the 
RAF-MEK-ERK pathway (e.g., clinically, to BRAF inhibition[28] and preclinically, to 
inhibitors of ERK dimerization[86,87]) correlated with suppression of cytoplasmic  
pERK.  We therefore evaluated the distribution of pERK in our human 
melanoma tissues, and found that levels of pERK were correlated with those of 
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PREX1 both in the nucleus (Figure 2-1C) and in the cytoplasm (Figure 2-1D).  Both 
nuclear and cytoplasmic ERK activity may contribute to increased expression of 
PREX1. 
  
PREX1 regulates invasion in a complex manner in both BRAF- and NRAS-
mutant melanoma cell lines 
An unexpected observation in our studies of PREX1 function in a mouse 
model of melanoma was that Prex1 deficiency greatly impaired metastatic but not 
tumorigenic growth.  This result contrasts with studies evaluating the role of PREX1 
overexpression in human breast cancer cells, where stable shRNA-mediated 
suppression of PREX1 reduced their tumorigenic growth[126-128].   We therefore  
compared the effect of PREX1 suppression in human melanoma cell lines on both 
proliferation and invasion in vitro.   
To evaluate the role of PREX1 overexpression in cell growth, we first used 
three independent siRNAs to knock down PREX1 in two BRAF-mutant (A375 and 
WM2664) and two NRAS-mutant cell lines (SK-MEL-119 and Mel224) (Figure 2-2A, 
upper panels).  We found that transient (72 h) suppression of PREX1 did not 
significantly reduce their proliferation in vitro (Figure 2-2A, lower panels), consistent 
with the lack of effect of Prex1 deficiency on the growth of primary melanomas in 
mice. Next, we evaluated the role of PREX1 in invasion by analysis of invasion 
through Matrigel towards serum as a chemoattractant. We observed a surprisingly 
heterogeneous response to PREX1 knockdown that was independent of BRAF or 
 40 
 
NRAS mutational status.  For example, the NRAS-mutant line SK-MEL-119 
exhibited a 60-70% decrease in invasion upon knockdown of PREX1 (p<0.0001, 
Figure 2-2B) whereas the BRAF-mutant cell line A375 conversely exhibited a ~2-fold 
increase (p<0.001).  In contrast, the already very low degree of directed invasion of 
the BRAF-mutant line WM2664 was unaffected by PREX1 knockdown.  Similarly, 
the invasive NRAS-mutant cell line Mel224 was largely unaffected, despite efficient 
knockdown of PREX1.  These data demonstrate that PREX1 plays a complex and 
variable role in directed invasion towards an attractant.  
 Next, we investigated the role of PREX1 in a three-dimensional spheroid 
formation and collagen invasion assay, which mimics the in vivo tumor environment 
of human skin[143].  Figure 2-2C illustrates both spheroid formation and the 
subsequent invasion of cells from the spheroid into the surrounding collagen matrix.  
In three of the four cell lines, knockdown of PREX1 impaired spheroid invasion into 
collagen, either trending (SK-MEL-119) or significantly so (Mel224, WM2664).  In 
contrast, A375 spheroids were defective in formation and did not invade the 
surrounding collagen matrix.  The nearly doubled total spheroid area of PREX1-
knockdown A375 cells compared to mismatch control cells observed after 4 days in 
culture was caused by a flattening of the three-dimensional spheroid structure and 
not by increased invasion or by increased proliferation; no change in proliferation 
occurred upon loss of PREX1 (Fig. 2-2A).  
Collectively, our results suggest a complex and context-dependent role for 
PREX1 in driving both directed invasion and three-dimensional spheroid collagen 
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outgrowth of human melanomas, and one that is not dependent on BRAF or NRAS 
mutational status.  
PREX1 regulates active, GTP-bound RAC1 but not CDC42 in melanoma cells 
Although PREX1 is considered a RAC-selective GEF[144], PREX1 is also 
active on CDC42[139]. We therefore investigated which Rho family small GTPases 
are activated downstream of PREX1 in human melanoma cells.  We found that  
knockdown of PREX1 decreased the levels of activated RAC1, as measured by 
RAC1-GTP pulldown, in both BRAF-mutant A375 and NRAS-mutant SK-MEL-119 
cells (Figure 2-3).  Despite the continued presence of other RacGEFs capable of 
inducing nucleotide exchange on RAC1, even incomplete loss of PREX1 was 
sufficient to cause a substantial decrease in RAC1-GTP (Figure 2-3).  This effect 
was selective for RAC1, as the levels of activated CDC42 did not decrease (Figure 
2-3).  These results support a role for PREX1 in regulating RAC1 activity and 
subsequent RAC1-driven invasive behavior of melanomas. 
We next asked if the loss of RAC1 was sufficient to phenocopy the 
impairment of invasion that we observed upon loss of PREX1.  We found that 
knockdown of either PREX1 or RAC1 with three independent siRNAs for each 
(Figure 2-4A) was sufficient to substantially impair spheroid formation of A375 cells, 
as demonstrated by an increase in the flattened spheroid area (Figure 2-4B,C).  The 
degree of impairment upon knockdown of RAC1 was highly significant (p<0.0001, 
Figure 4C) and comparable to the degree of impairment observed upon knockdown 
of PREX1 (p<0.0001, Figure 2-4C).  Next, we observed that loss of RAC1 (Figure 2-
4D) was sufficient to prevent the vast majority of SK-MEL-119 cell invasion in the 
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Boyden chamber assay (Figure 2-4E).  This decrease in invasion was similar to the 
decrease seen upon PREX1 knockdown (p<0.0001, Figure 2-4F).  The ability of 
RAC1 to phenocopy PREX1 in impairing both spheroid formation and directed 
invasion supports the idea that RAC1 is the most critical Rho family small GTPase 
downstream of PREX1 in regulating invasive melanoma behavior.  Of note, other 
Rho family small GTPases such as RND3 have also been shown to be regulated by 
the RAF-MEK-ERK pathway and to contribute to melanoma invasion and spheroid 
outgrowth[145,146].  However, as a Rho-like rather than a Rac-like GTPase, RND3 is 
unlikely to be a target of PREX1 in this context[147]. 
PREX1 protein levels are positively regulated by ERK activity in melanoma 
Our evaluation of human melanoma cell lines and tumor tissue found a 
correlation between phosphorylated ERK and PREX1 protein overexpression.  To 
directly address whether ERK activation is required for PREX1 overexpression, we 
evaluated whether pharmacologic inhibition of RAF-MEK-ERK signaling would 
reduce PREX1 protein levels in BRAF- and NRAS-mutant melanoma.  We first 
treated NRAS-mutant SK-MEL-119 cells with increasing concentrations of the MEK  
inhibitor trametinib.  The more effective the inhibition of MEK, as measured by 
decreasing levels of phosphorylated and activated ERK (pERK) and total MYC (an 
ERK substrate; ERK phosphorylation blocks degradation), the greater the decrease 
in PREX1 protein (Figures 2-5A,B), suggesting a direct correlation between ERK 
activity and PREX1 protein levels.  We next wanted to determine whether this dose-
dependent decrease in PREX1 protein would also occur when the ERK MAPK 
cascade was inhibited at different nodes, and whether such an effect is time-
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dependent. We therefore treated SK-MEL-119 cells with two different concentrations 
(1 x EC50 and 5 x EC50 for growth) of either trametinib or the ERK inhibitor 
SCH772984, for either 24 or 48 h (Figures 2-5C,D).  PREX1 protein levels tracked 
closely with the level of pERK at each concentration of inhibitor, and this was 
sustained for 48 h.  Next, we investigated whether PREX1 protein was similarly 
regulated downstream of the ERK-MAPK cascade in BRAF-mutant melanoma cells. 
We treated A375 cells similarly but with the BRAF inhibitor vemurafenib or 
SCH772984 for 24 or 48 h (Figures 2-5E,F).  Similarly to SK-MEL-119 cells, levels of 
PREX1 in A375 cells tracked closely with the levels of pERK and demonstrated a 
time-dependent effect.  In both SK-MEL-119 and A375 cells, phosphorylation of the 
ERK substrate RSK (pRSK) and total MYC served as effective markers to 
demonstrate inhibition of ERK, as we have observed in other settings[148].  These 
results indicate that ERK MAPK activity is an important contributor to the total 
amount of PREX1 protein in melanoma cells. 
PREX1 levels are regulated by ERK both transcriptionally and post-
transcriptionally in melanoma 
To determine if the loss of PREX1 protein upon blockade of the ERK MAPK 
cascade was due to loss of PREX1 mRNA, we treated two BRAF-mutant and two 
NRAS-mutant melanoma cell lines with ERK MAPK cascade inhibitors.  BRAF-
mutant A375 and WM2664 cells were treated for 24 h with vemurafenib or 
SCH772984 as above.  Taqman quantitative PCR  analysis revealed that PREX1 
mRNA, measured by two independent probes, did not change upon inhibition of 
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BRAF or ERK in A375 cells (Figure 2-6A) but decreased dose-dependently in 
WM2664 cells upon inhibition of either BRAF or ERK (Figure 2-6B).  NRAS-mutant 
cells were treated with trametinib or SCH772984 as above.  We observed that 
PREX1 mRNA also decreased upon ERK inhibition in both SK-MEL-119 (Figure 2-
6C) and Mel224 cells (Figure 2-6D).  Additional melanoma lines also exhibited 
reduced PREX1 mRNA levels when treated with inhibitors of the ERK MAPK 
cascade, including BRAF-mutant SK-MEL-28 and NRAS-mutant SK-MEL-147 cells 
(Figures 2-9A,B).  Thus, in the majority of melanoma cell lines, ERK MAPK regulates 
PREX1 protein levels both transcriptionally and post-transcriptionally.  
 That ERK MAPK activity altered PREX1 protein levels in A375 melanoma 
cells without changes at the transcriptional level suggested a post-transcriptional 
mechanism for ERK MAPK-mediated regulation of PREX1 protein in these cells.  To 
investigate this possibility, we treated A375 cells with vehicle or SCH772984 in the 
presence of the protein synthesis inhibitor cycloheximide at various time points over 
24 h (Figures 2-6E,F).  Inhibition of ERK led to greater loss of PREX1 protein in the  
presence of cycloheximide compared to vehicle-treated cells.  Similar results were 
obtained upon treatment of SK-MEL-119 cells with trametinib in the presence of 
cycloheximide (Figures 2-9C,D). These results indicate that ERK can regulate 
protein stability as well as transcription of PREX1 in melanoma cell lines.   
 Finally, we tested the possibility that PREX1 is not only an ERK target but 
also an ERK activator.  Since it has been demonstrated that PREX1 can regulate 
MEK-ERK signaling through RAC1 in breast cancer[149,128], we also examined 
whether PREX1 can regulate ERK1/2 phosphorylation in our melanoma lines.  We 
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found that knockdown of PREX1 did not alter ERK1/2 phosphorylation in the BRAF-
mutant cell lines, A375 and WM2664, or the NRAS-mutant cell lines, SK-MEL-119 
and Mel224 (Figures 2-10A,B and S4C,D, respectively).  
To determine the generality of ERK regulation of PREX1 expression in non-
melanoma tumor types, we also tested whether they held true in breast and prostate 
cancer cell lines.  PREX1 has been shown to be overexpressed in these tumor 
types, but the role of ERK in its expression has not been explored.  Unlike our 
observations in melanoma cells, we observed that inhibition of the ERK MAPK 
cascade in T47D and MCF7 breast cancer cells did not reduce PREX1 protein 
(Figures 2-11A,C) or mRNA (Figures 2-11B,D). Conversely, in PC-3 prostate cancer 
cells, inhibition of the ERK MAPK cascade reduced PREX1 mRNA levels (Figure 
S5F) but had minimal effects on PREX1 protein (Figure 2-11E).  These results 
support distinct mechanisms of regulating PREX1 expression in melanoma through 
ERK1/2 that do not apply in breast or prostate cancer, cancers in which BRAF and 
RAS mutation frequencies are low. Overall, our results support that both ERK 
regulation of PREX1 abundance and PREX1 regulation of ERK phosphorylation are 
context-dependent, and may differ between breast and prostate cancers and 
cutaneous melanoma. 
DISCUSSION 
 
 We determined that the ERK MAPK cascade plays an important role in 
driving PREX1 protein overexpression in both BRAF- and NRAS-mutant 
melanomas.  In contrast, ERK is not the key driver for PREX1 overexpression in 
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prostate[124,125] or in breast carcinomas[126,127,150,128], where its abundance is 
associated with HDAC-dependent [125] PREX1 gene transcription and with HDAC- 
and methylation-dependent PREX1 gene transcription[150] and gene 
amplification[126,150,128], respectively.  Thus, there are striking cancer-type differences 
in mechanisms driving PREX1 overexpression.  In support of this idea, PREX1 and 
PREX2 display distinct expression and mutation patterns in breast cancer, prostate 
cancer, and melanoma (Figure 2-7), and PREX1 in particular is differentially 
amplified in breast cancer, prostate cancer and cutaneous melanoma (Figure 2-8).  
Our findings also suggest that loss of PREX1-RAC1 signaling may contribute to the 
clinical response of patients with BRAF-mutant melanomas to BRAF and MEK 
inhibitors. 
The effectiveness of these inhibitors provides compelling evidence that 
aberrant ERK signaling is a major driver of melanoma growth.  Despite this clear 
driver role, the ERK targets important for melanoma growth remain poorly 
characterized. The ERK1/2 kinases can phosphorylate more than 200 known 
substrates[76,142] and serve as master regulators of numerous transcription factors[16], 
both directly and indirectly, through both transcriptional and post-translational 
mechanisms[151,152,16,148]  We have determined that ERK regulates PREX1 
expression levels in part via protein stability, a mechanism also not observed in 
other cancers. ERK regulation of PREX1 protein stability presents a previously 
unknown mechanism of maintaining PREX1 protein expression and may explain the 
basis for the relatively high PREX1 expression in malignant melanomas where the 
ERK MAPK cascade is upregulated. 
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 Finally, the PREX1-related RhoGEF PREX2 is activated by missense 
mutations in 25% of metastatic melanomas, especially by truncating mutations 
mutations[102,103], and mutational activation of the PREX1/2 target RAC1 has been 
observed in ~11% of melanomas[31,131]. The rarity of PREX1 truncating mutations 
and lack of apparent hotspots among the few missense mutations argue that this is 
not a significant mechanism of PREX1 activation in melanoma. Instead, our 
determination that PREX1 is overexpressed and regulated at multiple levels in 
response to the ERK MAPK cascade characterizes a third mechanism for driving 
aberrant RAC1 signaling in melanoma.  Our findings that loss of RAC1 phenocopies 
loss of PREX1 with respect to invasive behavior regardless of BRAF or NRAS 
mutation status supports the importance of the PREX1-RAC1 relationship as a 
promoter of melanoma cell invasion.  Interestingly, downregulation of the RacGEF 
TIAM1 by mutant BRAF was shown to enhance invasion of human melanoma 
cells[153].  Although PREX1 was not examined in that particular study, PREX1 has 
consistently demonstrated a positive role in invasion[124,105,154], whereas TIAM1 can 
be either a positive or a negative regulator of this process[155,156,153,99,157].  Thus, the 
relative input from different upstream activators of RAC1 can have a profound 
influence on melanoma invasion.  
 In summary, we have demonstrated that the ERK MAPK cascade mediates 
overexpression of PREX1 in melanoma at multiple levels, and by mechanisms that 
are distinct from those identified previously in other cancer types.  Our results 
contribute to a better understanding of how RacGEFs are modulated in distinct 
cancer contexts.  
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Figure 2-1. PREX1 protein levels are elevated in melanoma patient tumor tissues and 
cell lines, along with phospho-ERK.  (A) Western blot analysis of PREX1 protein, 
phospho-ERK (pERK) and total ERK1/2 in a panel of WT, BRAF- or NRAS-mutant human 
melanoma tumor cell lines. (B-D) Human tissue samples of benign melanocytic nevi and 
malignant skin cutaneous melanoma were subjected to IHC for PREX1 and pERK. Shown 
are (B) the distribution of PREX1 expression in nevi versus melanoma samples as 
measured by IHC; n=35 and 33, respectively. Samples were first binned according to no, 
low, medium or high staining intensity for each protein, and then the distribution was 
graphed to show the relationship between PREX1 and the percent of samples that stained 
positive for (C) nuclear pERK or (D) cytoplasmic pERK. 
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Figure 2-2.  PREX1 regulates spheroid formation and invasion, but not proliferation, 
of BRAF- and NRAS-mutant melanoma cells in a context-dependent manner.  (A)  
BRAF-mutant A375 and WM2664 and NRAS-mutant SK-MEL-119 and Mel224 cells were 
transfected with siRNA against PREX1 or a mismatch control (MM) for 48 h, and knockdown 
was confirmed by western blot (upper panels).  Apparent molecular weights are indicated to 
the right of each panel; vinculin served as a loading control. Fold changes in protein 
expression compared to MM control are shown in numbers below each blot.  Effects of 
PREX1 knockdown on growth in monolayer culture were determined by MTT assay at 72 hr 
(lower panels).  (B) To determine the effects of PREX1 knockdown on invasion, cells were 
seeded in the upper chamber of a Matrigel-coated Boyden chamber, and allowed to invade 
towards serum for 24 h, then stained and imaged.  ImageJ was used to quantitate invaded 
cells per field for 5 fields per insert in duplicate inserts (A375, SK-MEL-119, Mel224) or 
invaded cells over both inserts (WM2664). (C) For spheroid collagen invasion assays, 
spheroids were allowed to form for 4 days.  Total spheroid area was normalized to that of 
mismatch control-treated cells; impaired spheroid formation is indicated by increased area of 
the flattened spheroid.  WM2664, SK-MEL-119, and Mel224 spheroids were embedded in a 
collagen matrix and imaged (day 0) and the extent of cell outgrowth/invasion was imaged 3 
days later (thick gray lines).  Fold change in area from day 3 to day 0 was calculated in 
ImageJ. Data are represented as mean ± SD and statistical significance was evaluated by 
Student’s t-test, where *: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001.  Scale bar 
represents 250 µm for invasion assays and 500 µm for spheroids. Experiments shown are 
representative of two (WM2664, SK-MEL-119) or three (A375, SK-MEL-119) independent 
experiments.  
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Figure 2-3. PREX1 regulates active RAC1-GTP, but not active CDC42-GTP, in 
melanoma cells.  A375 and SK-MEL-119 cells were transfected with pooled siRNAs #1-3 
against PREX1 or MM control for 48 h, then starved overnight (18 h). RAC1-GTP and 
CDC42-GTP were measured by GST-PAK-PBD pulldown (A).  Apparent molecular weights 
are indicated to the right of each panel; vinculin served as a loading control. Quantification 
(mean ± SD) using ImageJ (B) is representative of two independent experiments. 
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Figure 2-4. RAC1 phenocopies PREX1 in regulating spheroid formation in A375 and 
invasion in SK-MEL-119.  A375 and SK-MEL-119 cells were transfected with siRNA 
against PREX1, RAC1, or MM control for 48 h before seeding into invasion chambers.  
Knockdown was confirmed by western blot in A375 (panel A) and SK-MEL-119 (panel D).  
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Apparent molecular weights are on the right of each panel; vinculin was a loading control. 
Total spheroid area of A375 cells was quantified after 4 days using ImageJ (white line); 
increased flattened spheroid area indicates impaired spheroid formation (panels B,C).  SK-
MEL-119 cells were starved overnight and seeded in a Boyden chamber assay with 20% 
serum as a chemoattractant and allowed to invade for 24h (10x magnification) (E). Stained 
inserts were quantified for invaded cells/field, 10 fields per condition, using ImageJ (F). Data 
are represented as mean ± SD. Student’s t-test, where *: p<0.05, **: p<0.01, ***: p<0.001, 
****: p<0.0001).  Scale bar represents 250 µm for invasion assays and 500 µm for 
spheroids. 
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Figure 2-5.  PREX1 protein levels are regulated by the ERK kinase cascade. NRAS-
mutant SK-MEL-119 cells were first treated with the indicated concentrations of MEKi 
trametinib for 48 h, and lysates immunoblotted for PREX1, pERK and MYC (A; quantified in 
B).  SK-MEL-119 cells were next treated with trametinib or the ERK inhibitor SCH772984 for 
24 or 48 h, and lysates probed for pERK and PREX1 (C; quantified in D), and for pRSK and 
total MYC to monitor ERK pathway inhibition (C).  Similarly, BRAF-mutant A375 cells were 
treated with the BRAF inhibitor vemurafenib or with SCH772984 for 24 or 48 h and lysates 
probed as above (E; quantified in F). Quantification is of n=3 experiments for SK-MEL-119 
and n=4 for A375. Data are represented as mean ± SD. 
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Figure 2-6. PREX1 levels are regulated by ERK both transcriptionally and post-
transcriptionally. BRAF-mutant A375 and WM2664 cells were treated with vemurafenib or 
SCH772984 for 24 h and PREX1 mRNA levels were measured by Taqman qPCR using two 
independent probes (A,B). NRAS-mutant SK-MEL-119 and Mel224 cells were treated with 
trametinib or SCH772984 for 24 h, and PREX1 mRNA measured as above (C,D). Taqman 
analyses indicate compiled results of n=2 experiments for WM2664 and Mel224, and n=3 
experiments for A375 and SK-MEL-119.  To test posttranscriptional regulation, A375 cells 
were treated with vehicle or SCH772984 in the presence of 50 µg/ml cycloheximide, and 
lysates were probed by western blot for PREX1, pERK and MYC (E). Quantification of 
PREX1 levels using ImageJ (F) is representative of n=2 independent experiments. Data are 
represented as mean ± SD. 
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Figure 2-7. PREX1 and PREX2 display distinct expression and mutation patterns in 
breast cancer, prostate cancer, and melanoma. cBioPortal was used to generate: (A) 
Alignment of PREX1 and PREX2 proteins with their mutation profiles in cutaneous 
melanoma. Distribution of PREX1 (B) and PREX2 (C) mRNA expression and mutation 
status in breast cancer, prostate cancer, and cutaneous melanoma TCGA samples. 
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Figure 2-8. PREX1 is differentially amplified in breast cancer, prostate cancer and 
cutaneous melanoma. PREX1 copy number analysis for TCGA melanoma (A), prostate 
(B), and breast cancer subtypes (C), generated from Oncomine. 
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Figure 2-9. PREX1 levels are regulated by ERK both transcriptionally and post-
transcriptionally. (A) BRAF-mutant SK-MEL-28 cells were treated with or without 
vemurafenib or SCH772984 for 24 h and PREX1 mRNA levels were measured by Taqman 
qPCR using two independent probes.  (B) NRAS-mutant SK-MEL-147 cells were treated 
with trametinib or SCH772984 for 24 h, and PREX1 mRNA levels were measured as above.  
(C) NRAS-mutant SK-MEL-119 cells were treated with vehicle or trametinib in the presence 
of 50 µg/ml cycloheximide for the indicated time points, and lysates were probed by western 
blot for PREX1, pERK/total ERK and MYC.  Results were quantified using ImageJ (D). Data 
are represented as mean ± SD. 
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Figure 2-10. Loss of PREX1 does not alter ERK phosphorylation. Cells were first treated 
with siRNA against PREX1 or a mismatch control (MM) for 48 h.  Lysates of BRAF-mutant 
cell lines A375 (panel A) and WM2664 (panel B), and NRAS-mutant cell lines SK-MEL-119 
(panel C) and Mel224 (panel D), were analyzed by western blot for PREX1 and pERK/total 
ERK. Apparent molecular weights are indicated to the right of each panel; vinculin served as 
a loading control. 
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Figure 2-11. ERK differentially regulates PREX1 in breast and prostate cancer cells. 
T47D (A,B) and MCF7 (C,D) breast cancer cells and PC-3 (E,F) prostate cancer cells were 
treated with or without trametinib or SCH772984 for 24 or 48 h. Lysates were probed by 
western blot for PREX1, pERK/total ERK and MYC (A,C,E). Apparent molecular weights are 
indicated to the right of each panel; vinculin served as a loading control. Fold-change in 
PREX1 protein levels are indicated by the numbers under the PREX1 panels. PREX1 
mRNA levels were measured by Taqman qPCR after 24 h of drug treatment (B,D,F). Data 
are represented as mean ± SD. 
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CHAPTER III: CONCURRENT P38 MAPK INHIBITION ENHANCES ERK 
INHIBITOR ANTI-TUMOR ACTIVITY IN KRAS-MUTANT CANCERS3 
 
 
 
OVERVIEW 
 
We recently demonstrated that pharmacologic inhibition of the ERK mitogen-
activated protein kinases (MAPKs) may be an effective therapeutic approach for the 
treatment of KRAS-mutant pancreatic ductal adenocarcinoma (PDAC).  Since we 
anticipate that treatment-induced resistance will likely limit the success of ERK 
inhibitor therapy, we applied a CRISPR/Cas9-based genetic loss-of-function screen 
to identify genetic drivers of resistance to ERK inhibition.  We identified loss of 
MAPK14, encoding the p38 MAPK, as causing increased sensitivity to the ERK1/2-
selective inhibitor SCH772984 (ERKi) in KRAS-mutant PDAC, lung and colorectal 
carcinoma cell lines.  We then focused on KRAS-mutant PDAC to assess p38 
signaling as a modulator of ERK inhibitor (ERKi) sensitivity.  Conversely, ectopic 
overexpression of p38 reduced ERKi sensitivity.  Cotreatment with a clinical 
candidate pharmacologic inhibitor of p38, LY2228820 (ralimetinib, p38i), 
synergistically enhanced ERKi activity in both anchorage-dependent and anchorage-
independent growth and led to increased cell cycle arrest but not apoptosis.  Finally, 
we assessed a mechanistic basis for p38 modulation of ERKi sensitivity.  We found 
                                                          
3 This chapter is currently under revision for publication. The other authors are Peter S. 
Winter, Andrew M. Waters, Kris C. Wood, Adrienne D. Cox, and Channing J. Der.  All 
figures represent the work of Meagan B. Ryan, with the exception of Figures 3-1 and 3-4. 
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that ERKi alone enhanced p38 signaling and that concurrent p38i accelerated 
ERKi-mediated loss of MYC protein.  We conclude that concurrent p38i treatment 
may be an effective combination therapy to enhance ERKi anti-tumor activity in 
PDAC and other KRAS-mutant cancers.  
INTRODUCTION 
 
 Pancreatic cancer is currently the third leading cause of cancer deaths in the 
United States with treatments limited to surgical resection or chemotherapy with 
gemcitabine, FOLFIRINOX (fluorouracil, folinic acid [leucovorin], irinotecan, and 
oxaliplatin) or gemcitabine plus nanoparticle albumin-bound paclitaxel (nab-
paclitaxel)[158,159].  Pancreatic ductal adenocarcinomas (PDAC) are driven by mutant 
KRAS in >95% of cases[14].  Currently, although no treatments have successfully 
targeted mutant KRAS in the clinic, there has been a renewed interest in developing 
direct KRAS inhibitors to block mutant-RAS function[3].  To date, the most effective 
and promising efforts targeting KRAS-dependence in PDAC and other RAS-mutant 
cancers involve blocking KRAS effector signaling, in particular blocking the RAF-
MEK-ERK mitogen activated protein kinase (MAPK) signaling cascade[133].  
Activation of the RAF-MEK-ERK cascade is sufficient and necessary for both the 
formation and maintenance of PDAC[160,17].   
 Pharmacologic inhibition of the RAF-MEK-ERK cascade presents a promising 
therapeutic option in KRAS-mutant cancers, including PDAC, based on genetic 
studies showing dependency on the RAF, MEK or ERK nodes of the 
cascade[161,19,20].  There are currently over 30 inhibitors of the RAF-MEK-ERK 
cascade under clinical evaluation in cancer[3,133].  RAF phosphorylates and activates 
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MEK, which in turn phosphorylates and activates ERK, which can phosphorylate 
>200 cytoplasmic and nuclear substrates[76,142].  RAF and MEK inhibitors have had 
limited success in the clinic due to paradoxical activation of the RAF-MEK-ERK 
cascade upon treatment with BRAF-selective inhibitors in RAS-mutant cancers as 
well as due to kinome reprogramming after treatment with RAF or MEK inhibitors, all 
which lead to the re-activation of ERK[162,33,54,37].  Thus, direct pharmacologic 
inhibition of ERK may be the answer to successfully inhibiting the RAF-MEK-ERK 
cascade in KRAS-mutant pancreatic cancer.  The allosteric and ATP-competitive 
ERK1/2 inhibitor SCH772984 effectively reduces the growth of cancers harboring 
NRAS, BRAF, or KRAS mutations, including melanomas resistant to the BRAF 
inhibitor vemurafenib[60].  Recent work from our group has shown that SCH772984 is 
effective in reducing the growth of a subset of PDAC cell lines, through a MYC 
dependent mechanism[148].  PDAC cell lines that were insensitive to MEK inhibition 
were sensitive to SCH772984 and the ERK inhibitor BVD-523, and both ERK 
inhibitors synergized with the AKT inhibitor AZD8186.  Additional potential 
mechanisms of resistance to SCH772984, including PI3K, Notch, and the stress 
activated MAPK p38α (MAPK14), were also identified through drug sensitivity and 
resistance testing (DSRT) and cancer toolkit screening (CTK)[112,113,148]. 
 MAPK14 (p38α), along with MAPK11 (p38β), are MAP kinases strongly 
activated by cellular stress, cytokines, and other exogenous stimuli.  In cancer, p38α 
has been found to play both a tumor promoting and a tumor suppressive role in 
regulating the balance between cell survival and cell death, in a cancer type 
dependent manner [109,163].  In PDAC, p38 can paradoxically play a growth 
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suppressive role in untreated tumors while also conferring resistance to gemcitabine 
through p38 activation in both the tumor cells and cancer associated fibroblasts 
[110,111,164].  Evidence in PDAC and other tumor types suggests a broader role for p38 
in conferring therapeutic resistance to radiotherapy, chemotherapy, and targeted 
therapies, and consequently p38 yields a potential target for combination therapies 
[165,27,166,167].  A number of inhibitors of p38 are under clinical evaluation in 
inflammatory diseases and cancer, including BIRB-796 (doramapimod), GW-856553 
(losmapimod), and LY2228820 (ralimetinib)[168,169].  In this study, I validated MAPK14 
(p38α) as a potential mechanism of resistance to ERK inhibition and evaluated the 
clinical candidate p38 inhibitor LY2228820 as a combination strategy with ERK 
inhibitors in KRAS-mutant PDAC. 
 
MATERIALS AND METHODS 
 
Cell  lines  and inhibitors 
PDAC cell lines were obtained from ATCC and maintained in either DMEM or 
RPMI-1640 supplemented with 10% fetal calf serum, and were not cultured longer 
than 6 months from receipt from cell banks.  LY2228820, SCH772984, and BVD-523 
were purchased from Selleckchem. 
CRISPR/Cas9 
A barcoded lentiviral library consisting of sgRNA against 2390 genes, 5 
constructs per gene, was packaged, pooled, and infected at a multiplicity of infection 
(MOI) of 0.3 in PDAC, colorectal, or lung cell lines and cells were selected with 
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puromycin (2 µg/ml) for 48 h.  Stably selected sgRNA infected cells were divided into 
vehicle and SCH772984 treatment groups and treated at GI50 of proliferation (SCH) 
or equivalent concentration of DMSO.  Drug was refreshed every 3 days and cell 
populations were expanded for 4 weeks. Genomic DNA was isolated using the 
Qiagen DNeasy Blood and Tissue Kit.  Genomic DNA samples were prepared for 
Illumina Sequencing by PCR amplification of individual construct barcodes, using a 
common P5 Illumina adapter primer (PGK-Illumina-F) and a unique P7 Illumina 
barcoded adapter primer.  Illumina sequencing and analysis of vehicle treated 
samples vs. drug treatment samples was performed as outlined previously[113].   
Inhibitor treatment assays 
Sensitivity of PDAC cells to LY2228820, alone or in combination with 
SCH772984, was determined by MTT assay. Briefly, LY2228820 was serially diluted 
from 10 μM to 0.002 μM in a 96 well plate.  For anchorage-dependent inhibitor 
studies, SCH772984 was serially diluted from 30 µM to 0.007 µM in the presence of 
0, 0.4, 2, or 10 µM LY2228820.  Cells were seeded at a density of 2-3 x 103 cells per 
well and allowed to proliferate at 37°C and 5% CO2 for 72 h. before incubation for 3 
h in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT).  MTT was 
solubilized in DMSO and the absorbance was read at A570.  For anchorage-
independent inhibitor studies, cells were treated with inhibitor as in anchorage-
dependent assays.  Cells were seeded at a density of 5-10 x 103 cells per well in 1% 
SeaPrep Agarose (Lonza) in plates coated with 0.6% Bacto Agar and allowed to 
proliferate at 37°C and 5% CO2 for 72 h before incubation with AlamarBlue for 2-3 h. 
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Drug treatment and western blotting 
PDAC cells were treated with LY2228820, SCH772984, or a combination for 
2, 6, 24, or 72 h before samples were collected in RIPA lysis buffer.  Whole cell 
lysates were resolved on 10-12% SDS-PAGE gels and western blotting was 
performed using antibodies to phospho-MKK3 (Ser189)/-MKK6 (Ser207), phospho-
p38 (Thr180/Tyr182), total p38, phospho-MK2 (Thr334), total MK2, phospho-HSP27 
(Ser82), total HSP27, phospho-ERK1/2 (Thr202/Tyr204), total ERK1/2, phospho-
RSK (Thr359/Ser363), total RSK1/2/3, c-Myc (MYC), phospho-Rb (Ser807/811), 
cyclin B1, cyclin D1, and PARP (Cell Signaling); vinculin (Sigma); and p16 (Abcam).  
HRP-conjugated anti-mouse and anti-rabbit secondary antibodies were from Thermo 
Fisher. 
Apoptosis and cell cycle analysis 
PDAC cell lines were treated with LY2228820 (2 µM), SCH7772984 (625 nM) 
or combination for 72 h before apoptosis and cell cycle analysis by flow cytometry.  
Apoptosis analyses were performed with the TACS® Annexin V-FITC Kit (Trevigen) 
following the manufacturer’s protocol.  Briefly, spent culture medium containing 
detached cells was collected and mixed with trypsinized cells and centrifuged at 300 
x g for 5 min.  Cells were washed once in ice-cold 1X PBS and incubated in Annexin 
V Incubation Reagent (1% Annexin V-FITC, 1X Propidium Iodide Solution, in 1X 
calcium-containing binding buffer) at room temperature for 15 min in the dark.  Cells 
were analyzed on a BD LSRFortessa flow cytometer.  For cell cycle analysis, cells 
were harvested, washed once in 1X PBS, and resuspended in fresh PBS.  Ten 
volumes of ice cold 70% ethanol were added to each tube dropwise while vortexing 
gently.  Cells were incubated overnight at 4°C.  The fixed cells were then washed 
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once in 1X PBS, resuspended in 1X PBS containing 40 µg/ml propidium iodide and 
100 µg/ml RNase A (both from Life Technologies) and incubated at 37°C overnight.  
Cells were analyzed on a BD LSRFortessa flow cytometer. 
Quantitative PCR 
Total RNA was isolated using an RNeasy kit (Qiagen) and reverse 
transcription was performed using the High Capacity RNA-to-cDNA kit (Thermo 
Fisher).  Real time quantitative Taqman PCR was performed on the QuantStudio 6 
Flex (Thermo Fisher) with FAM/MGB labeled probes (Thermo Fisher) against 
HSPB1 (Hs00356629_g1), MYC (Hs00153408_m1) and endogenous control 
VIC/TAMRA labeled β-actin.   
Graphical analysis 
Data were analyzed using GraphPad Prism 6 software and curve fit and GI50 
values were generated as indicated in the Figure Legends. 
 
RESULTS 
 
CRISPR/Cas9 screening identifies MAPK14 (p38α) as a sensitizer to the ERK 
inhibitor SCH772984 
 
We recently demonstrated that direct inhibition of ERK with the inhibitor 
SCH772984 is effective in reducing proliferation of a subset of KRAS-mutant 
pancreatic cancer cell lines.  However, mechanisms of resistance to this new class 
of inhibitors targeting ERK have not been fully characterized[148].  Our previous 
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efforts have identified the PI3K-AKT-mTOR, Notch, and p38 pathways as a potential 
mechanism of resistance to ERK inhibitors in PDAC. We next sought both to validate 
previously identified hits and also to identify additional pathways that can confer 
resistance to the ERK inhibitor SCH772984 in KRAS-mutant lung, colorectal, and 
pancreatic cancers.  In an unbiased genetic loss-of-function screen, we found that 
CRISPR/Cas9 deletion of MAPK14, encoding p38, increased the sensitivity of 
KRAS-mutant lung, colorectal and pancreatic cell lines to the growth inhibitory 
activity of the ERK inhibitor SCH772984.   
p38 inhibition does not impair the proliferation of PDAC cell lines 
To determine basal levels of p38 MAPK and ERK MAPK pathway activity in 
PDAC, I performed Western blot analyses on a panel of 7 established and 7 patient-
derived xenograft (PDX) cell lines.  Despite similar levels of total p38 protein across 
all cell lines, levels of phosphorylated p38 (pp38) varied from low (AsPC-1, CFPAC-
1, HPAC, HPAF-II, and Pa18c) to high (MIA PaCa-2, Panc-1, Panc10.05) (Figure 3-
2A). Phosphorylated MKK3 and MKK6, the upstream activator of p38 also varied 
highly, as did both phosphorylated and total MAPKAPK-2 (MK2) and HSP27 
downstream of p38.  Likewise, expression and phosphorylation of ERK MAPK 
signaling components also varied widely among PDAC cell lines (Figure 3-2A).  High 
levels of phosphorylated ERK (Pa16c) did not correlate with high levels of 
phosphorylated RSK, a well characterized substrate of ERK[170].  Levels of MYC, 
both a substrate of ERK and a protein transcriptionally regulated by ERK, also varied 
widely among the panel of cell lines (Figure 3-2A). 
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To determine if pharmacologic inhibition of p38 is sufficient to inhibit PDAC 
growth, I used the clinical candidate p38α/β inhibitor LY2228820 to treat cells in 2D 
growth assays.  LY2228820 (ralimetinib) is a potent and selective ATP-competitive 
inhibitor of p38α/β and has a 15-50 fold selectivity over JNK1/2/3, while not inhbiting 
p38δ/γ, ERK1/2, or 176 other kinases[168].  In a panel of 5 established (AsPC-1, 
HPAC, HPAF-II, MIA PaCa-2, and Panc-1) and 3 PDX (Pa02c, Pa03c,and Pa16c) 
PDAC cell lines, LY2228820 did not appreciably reduce anchorage-dependent 
growth, with no GI50 calculated after 72 h of up to 10 µM inhibitor treatment (Figure 
3-2B).  However, LY2228820 potently inhibited the p38 MAPK signaling cascade at 
both 6 and 24 h in the established cell lines AsPC-1, HPAC, and MIA PaCa-2 
(Figure 3-2C).  Phosphorylation of HSP27, a well characterized protein regulated by 
p38, was reduced in a dose dependent fashion in all three cell lines, with maximum 
reduction in signal at 24 h of LY2228820 treatment.  Treatment with LY2228820 also 
induced rapid phosphorylation of the upstream activator of p38, MKK3/6, which in 
turn led to an increase in phosphorylation of p38; however, inhibition of the 
downstream target HSP27 was maintained, suggesting effective inhibition of p38.  
These results collectively suggest that p38α/β activity is not necessary for 
maintaining PDAC growth and that it may act in a compensatory pathway when ERK 
is inhibited. 
Concurrent inhibition of p38 enhances ERK inhibitor impairment of PDAC 
growth 
 Although the p38 inhibitor LY2228820 did not impair PDAC cell line growth as 
a single agent, it potently inhibited the pathway at nanomolar concentrations and 
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thus presents a novel potential combination treatment with ERK inhibitors.   PDAC 
cell lines exhibited varying sensitivity to the ERK inhibitor SCH772984 when 
measured by maximal inhibition of growth and GI50 concentration: the AsPC-1 cell 
line exhibited the least sensitivity to SCH772984, while the HPAC and MIA PaCa-2 
cell lines were highly sensitive to the inhibitor (Figure 3-3A,B).  To determine 
whether LY2228820 sensitizes PDAC cell lines to SCH77284, AsPC-1, HPAC, and 
MIA PaCa-2 cells were treated with a constant dose of LY2228820 in the presence 
of a dose titration of SCH772984.  After 72 h of growth on plastic, LY2228820 
sensitized cells to SCH772984 in a dose dependent fashion as measured by GI50 
shift (Figure 3-3A).  I also determined that LY2228820 sensitized AsPC-1, HPAC, 
and MIA PaCa-2 cell lines to SCH772984 in a 3D soft agar assay.  After 7 days of 
growth in soft agar, LY2228820 sensitized cells to SCH772984 in a dose dependent 
fashion as measured by GI50 shift (Figure 3-3B).  The fold shift in sensitivity to 
SCH772984 was greater in soft agar compared to growth on plastic for all cell lines. 
 I also expanded the study to an additional ERK inhibitor BVD-523, a clinical 
candidate inhibitor currently under investigation in combination with nab-paclitaxel 
and gemcitabine in pancreatic cancer (NCT02608229).  Previous work from our 
group has demonstrated that BVD-523, an ATP-competitive ERK inhibitor, has a 
similar efficacy in inhibiting growth in a subset of PDAC cell lines, which generally 
exhibit sensitivity or resistance to both inhibitors[148].  To determine whether 
LY2228820 sensitizes PDAC cell lines to BVD-523, AsPC-1, HPAC, and MIA PaCa-
2 cells were treated with a constant dose of LY2228820 in the presence of a dose 
titration of SCH772984.  After 72 h of growth on plastic, LY2228820 sensitized cells 
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to BVD-523 in a dose dependent manner as measured by GI50 shift (Figure 3-7A, B).  
These results demonstrate that concurrent inhibition with p38 sensitizes PDAC cell 
lines to structurally and mechanistically distinct ERK inhibitors and that ERK 
inhibitors may share p38 as a common mechanism of therapeutic resistance. 
 
Concurrent inhibition of both p38 and ERK causes G0/G1 cell cycle arrest   
 PDAC cell lines exhibit varying sensitivity to ERK inhibitors such as 
SCH772984. Work from our group has shown that treatment with SCH772984 
causes apoptosis after short term treatment whereas it induces a senescence like 
phenotype after longer term treatment[148].  We first asked if the p38 inhibitor 
LY2228820 enhances the early induction of apoptosis by the ERK inhibitor 
SCH772984 in the same three PDAC cell lines as above.  After 72 h of treatment 
with SCH772984, both AsPC-1 and HPAC showed a modest increase in apoptotic 
cells, as measured by cells staining positive for Annexin V (early apoptosis), or for 
both Annexin V and propidium iodide (late apoptosis) (Figure 3-4A-B).  MIA PaCa-2 
cells displayed a much stronger induction of apoptosis, with only 30% of cells 
remaining healthy (PI-/Annexin V-) after treatment with SCH772984.  In all three cell 
lines, concurrent LY2228820 and SCH772984 treatment did not enhance the level of 
apoptosis induced by SCH772984 alone.  These findings were supported by the 
presence of cleaved PARP in only the MIA PaCa-2 cells treated with SCH772984 
alone or with concurrent SCH772984 and LY2228820 (Figure 3-4C).  AsPC-1 and 
HPAC cells did not exhibit cleaved PARP under any inhibitor treatment condition. 
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 Since enhanced induction of apoptosis was not observed with concurrent p38 
and ERK inhibition in PDAC cell lines, we next determined if LY2228820 could 
perturb their cell cycle progression in the presence of SCH772984.  Treatment with 
SCH772984 for 72 h reduced markers of cell cycle progression as measured by 
phospho-Rb, cyclin D1 (G1 progression), cyclin B1 (progression through M) in all 
three cell lines (Figure 3-4C).  Loss of these cell cycle progression markers was 
enhanced by LY2228820 in both AsPC-1 and MIA PaCa-2 cells.  However, the 
negative cell cycle regulator p16 was elevated in the HPAC cell line only upon 
SCH772984 treatment. Using flow cytometry to measure total DNA content, we 
observed that treatment with ERK inhibitor alone was sufficient to induce an almost 
complete G0/G1 cell cycle arrest in HPAC cells, and a modest increase in G0/G1 in 
MIA PaCa-2 cells, whereas the percentage of AsPC-1 cells arrested in G0/G1 did not 
increase upon treatment with SCH772984 alone (Figure 3-4D).  Adding concurrent 
inhibition of p38 increased the percentage of MIA PaCa-2 and AsPC-1 cells arrested 
in G0/G1.  Collectively, our results show that concurrent inhibition of the ERK and 
p38 MAPK cascades converges on cell cycle regulation in PDAC cell lines. 
SCH772984 inhibition of ERK causes increased p38 signaling 
Since CRISPR/Cas9 genetic manipulation and pharmacologic inhibition of 
p38 signaling both modulated sensitivity to SCH772984 and enhanced G0/G1 cell 
cycle arrest, we speculated that ERK inhibition may cause alterations in p38 
signaling.  The p38 MAPK cascade is one of the stress activated MAPK cascades 
and can play dual roles in cancer by mediating both cell survival and cell death, 
depending on tumor type and mutational background[109].  The p38 MAPK cascade 
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can also contribute to therapeutic response to both targeted therapies and 
chemotherapeutics.  In hepatocellular carcinoma, MAPK14 (p38α) was found to 
confer resistance to the RAF and VEGFR inhibitor sorafenib, with activation of the 
p38 signaling cascade occurring after long term treatment[166].  In BRAFV600E-mutant 
melanomas, MAPK hyperactivation, including both p38 and JNK pathways, 
contributes to therapeutic resistance to the BRAF-selective inhibitor vemurafenib[27].  
MEK inhibitors have also been shown to induce dynamic kinome reprogramming in 
triple negative breast cancers, leading to the activation of multiple kinases including 
p38α[54]. Since treatment with both RAF and MEK inhibitors can lead to activation of 
p38 MAPK in multiple tumor types, we wanted to know if treatment of PDAC cell 
lines with the ERK inhibitor could also activate the p38 MAPK cascade. 
Three PDAC cell lines, AsPC-1, HPAC, and MIA PaCa-2, were treated with 
the ERK inhibitor SCH772984 for 24 or 72 h.  In all three cell lines, ERK was 
inhibited in a dose-dependent fashion as seen in the reduction of phospho-RSK and 
total levels of MYC.  Concurrently, levels of phospho-p38 and phospho-HSP27 
increased in both a time- and dose-dependent fashion, with maximal pathway 
induction occurring at 72 h (Figure 3-5A).  Except in the MIA PaCa-2 cell line, 
phosphorylation of MKK3/6, the upstream activator of p38α/β, was also increased, 
as was total HSP27 protein.  Similar results were seen after treatment with the ERK 
inhibitor BVD-523, where inhibition of ERK signaling was associated with increased 
phospho-p38, phospho-HSP27 and increased total HSP27 protein (Figure 3-7B). 
HSP27 expression can be regulated by the ERK pathway through the 
transcription factor HSF1 and HSP27 is itself a potential mechanism of resistance in 
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pancreatic cancer[110].  The increased protein levels of HSP27 following SCH772984 
treatment are due to an increase in HSP27 (HSP27) mRNA in AsPC-1, HPAC, and 
MIA PaCa-2 cells, where increasing expression of HSP27 mRNA correlated with an 
increasing dose of ERK inhibitor (Figure 3-5B).  Collectively, our results suggest that 
pharmacologic inhibition of ERK signaling led to increased p38 MAPK cascade 
activity, both upstream and downstream of p38.   
Concurrent inhibition of p38 can enhance ERK inhibitor treatment-induced 
loss of MYC protein expression  
 Both ERK and p38 are the terminal nodes of their respective MAPK signaling 
cascades.  They can phosphorylate many overlapping downstream substrates and 
subsequently regulate diverse cellular processes, including cell survival and 
proliferation and response to cellular stress[108].  Previous work from our lab has 
identified MYC as a critical substrate downstream of ERK and a marker of sensitivity 
or resistance of PDAC to SCH772984[148].   Therefore, we evaluated if MYC protein 
loss was a possible mechanism for synergy of concurrent ERK and p38 inhibition in 
PDAC.  The AsPC-1 cell line exhibited enhanced downregulation of total MYC 
protein in the presence of constant SCH772984 and increasing concentrations of 
LY2228820 starting at 2 h of concurrent inhibitor treatment (Figure 3-6A).  The loss 
of MYC protein was enhanced over time, with maximal loss of MYC occurring after 
72 h of treatment.  Both the ERK and p38 signaling pathways remained fully 
inhibited, as indicated by phospho-RSK and phospho-HSP27, respectively.  
However, the same synergistic loss of MYC protein was not seen in two other PDAC 
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cell lines, HPAC and MIA PaCa-2, indicating that the basis for synergy between ERK 
and p38 inhibition is not always dependent on MYC (Figure 3-8). 
 Although MYC presents a potential mechanism for synergy of concurrent 
ERK and p38 inhibition in PDAC, it was not known whether LY2228820 alone could 
regulate MYC protein levels, or whether the loss of MYC protein seen upon 
combination treatment was due to transcriptional, post-transcriptional or post-
translational mechanisms.  To address these questions, we treated AsPC-1 cells for 
24 h with increasing doses of LY2228820 in the presence or absence of SCH772984 
and then assessed the levels of MYC protein and mRNA.  LY2228820 treatment 
alone was not sufficient to regulate MYC protein; MYC protein levels were reduced 
only in the presence of SCH772984 (Figure 3-6B).  Similarly, increased loss of MYC 
transcript was seen only in the presence of both LY2228820 and SCH772984 after 6 
and 24 h of inhibitor treatment (Figure 3-6C).  Loss of MYC in the presence of 
SCH772984, LY222820, or a combination of the two inhibitors was not due to post-
translational regulation, as shown by similarly decreased protein levels over time in 
the presence of the translational inhibitor cycloheximide (Figure 3-9A,B).  Further, 
although the p38 pathway has been found to regulate mRNA stability under 
conditions of cell stress[171], the loss of MYC transcript seen upon concurrent 
treatment with LY2228820 and SCH772984 was not due to destabilization of MYC 
mRNA, as shown by similarly decreased message levels over time in the presence 
of the transcriptional inhibitor, actinomycin D (Figure 3-9C).  These short term results 
differ from a previous finding by our group showing that long term treatment with 
SCH772984 resulted in post-translational loss of MYC protein in ERK inhibitor 
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sensitive PDAC cell lines. Collectively, my findings reveal an additional novel 
regulatory mechanism for maintenance of MYC protein levels downstream of the 
ERK MAPK and p38 MAPK signaling cascades. 
DISCUSSION 
 
  We have shown that p38 inhibition can synergize with ERK inhibition in 
KRAS-mutant PDAC and that MAPK14 (p38α) presents a novel potential 
mechanism of resistance to ERK inhibitors.  Targeting the RAF-MEK-ERK cascade 
presents a promising approach to treating KRAS-mutant PDAC, as well as other 
RAS-driven cancers, emphasizing the need to characterize potential resistance 
mechanisms, such as p38, in order for this treatment approach to become 
successful.  Re-activation of ERK by various means are key mechanisms of 
resistance to upstream pathway inhibitors, such as EGFR, RAF and MEK 
inhibitors[172,173,27,72,174,175], and thus, direct ERK inhibition can overcome these 
resistance mechanisms[73,60].  Resistance to ERK inhibitors can also arise, through 
mutation in ERK itself and through activation of a parallel pathway such as the PI3K-
AKT-mTOR pathway[15,148].  Our study demonstrates that compensatory activation of 
the parallel p38 MAPK pathway occurs in response to the ERK inhibitors 
SCH772984 and BVD-523 and that inhibition of p38 can sensitize PDAC cell lines to 
ERK inhibition.   
 The p38 MAPK pathway and its downstream components have been 
identified previously as a potential resistance mechanism for both cytotoxic 
chemotherapeutics and targeted inhibitors.  Inhibition of p38 or its substrate MK2 
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synergized with SMAC mimetics in leukemias and MK2 inhibition synergized with 
Chk1 inhibition in KRAS-mutant cancers[176,177], and MK2 was found to confer 
resistance to cisplatin in non-small cell lung cancer[165].  Phosphorylated and total 
protein levels of the heat shock protein HSP27, a substrate of MK2, were elevated in 
our PDAC cell lines in response to SCH772984 or BVD-523 treatment.  Heat shock 
proteins, including HSP27, are generally elevated in cancer and increased basal 
levels, or increase in expression levels in response to cancer therapies, can lead to 
therapeutic resistance[178].  Further, HSP27 can contribute to gemcitabine resistance 
in pancreatic cancer, which can be overcome by inhibition of HSP27 with OGX-
427[179,110].  Our study suggests that HSP27 may play a key role in p38 mediated 
resistance to ERK inhibitors in PDAC. 
 Our findings also support a role for cell cycle arrest but not apoptosis in 
reducing growth upon concurrent ERK and p38 inhibition. Although blocking p38 in 
some cellular contexts can induce apoptosis, including when combined with MEK 
inhibitors[180], we did not see levels of apoptosis induced by SCH772984 increase 
upon the addition of LY2228820. However, we did see enhanced percentages of 
cells in G0/G1 upon concurrent p38 and ERK inhibition.  The cell cycle arrest seen 
upon concurrent p38 and ERK inhibition may be due in part to enhanced loss of 
MYC protein, although this was not seen in all cell lines.  An enhanced 
downregulation of phosphorylation of the cell cycle marker Rb was seen with both 
inhibitors, suggesting a convergence point of both pathways.  ERK has been found 
to regulate the cell cycle, and inhibition of ERK downregulates phophorlyation of Rb 
and cyclin D1 expression in PDAC[181,148].  Phosphorylation of Rb by p38 has been 
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found to also regulate its activity independent of the cyclin-dependent kinases[182-184].  
These results both support our previous findings that ERK inhibitors regulate the cell 
cycle and senescence and demonstrate that the addition of a p38 inhibitor can 
enhance these effects and lead to a marked reduction in PDAC cell growth. 
 p38 inhibitors have seen limited success as single agent therapies in cancer 
yet have shown promise as combination strategies both with cytotoxic 
chemotherapies and with targeted therapies against oncogenic pathways.  We have 
demonstrated that the p38 inhibitor LY2228820 can overcome ERK inhibitor 
resistance and enhance the efficacy of SCH772984 in PDAC, providing a rationale 
for combined treatment with these agents that can potentially be applied to other 
KRAS-mutant cancers. 
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Figure 3-1.  Loss-of-function genetic screen identifies MAPK14 (p38α) as a regulator 
of ERK inhibitor sensitivity in KRAS-mutant cancer cell lines. (A) Gene targets of our 
CRISPR/Cas9 sgRNA library.  The library was comprised of lentivirus expression vectors 
encoding five single-guide RNAs (sgRNAs) targeting distinct sequences in 2,390 genes.  
Shown are the protein classes encoded by these genes.  (B) SCH772984 sensitive cell lines 
were infected with the lentivirus sgRNA library, followed by selection in growth medium 
supplemented with SCH772984 at the GI50 for each cell line, for approximately 4 weeks.  
Genomic DNA was then isolated, followed by DNA sequencing to identify DNA barcode 
enrichment/depletion.  (C)  Heatmap indicating enrichment (blue) or depletion (red) of 
barcode sequences in SCH772984 treated versus control cell populations. 
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Figure 3-2. Inhibition of p38 does not impair the growth of PDAC cell lines.  (A) PDAC 
cell lines exhibit variable levels of basal p38 signaling. Western blot analyses were 
performed for phosphorylated and total p38 pathway proteins, including MKK3/6, p38, MK2, 
HSP27, and for ERK pathway proteins, including phosphorylated and total ERK, RSK, and 
total MYC. Vinculin served as a loading control.  (B)  PDAC cell lines were treated for 72 h 
with a range of LY2228820 concentrations and anchorage-dependent growth was monitored 
by the MTT viability assay.  (C) PDAC cell lines were treated with the indicated 
concentrations of LY2228820 for 6 or 24 h and western blot analysis was performed for p38 
pathway proteins as in panel A. 
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Figure 3-3. Concurrent inhibition of p38 enhances ERK inhibitor-mediated reduction 
of anchorage-dependent and -independent growth in PDAC cell lines. (A) 72 h MTT 
assay of AsPC-1, HPAC, and MIA PaCa-2 cell lines treated with indicated concentrations of 
the p38 inhibitor LY2228820 and a dose titration of the ERK inhibitor SCH772984.  Each 
growth assay is representative of n=3 experiments. Lower panels, compiled results of MTT 
assays shown in each upper panel, presented as fold GI50 shift, n=3 assays. (B) AlamarBlue 
readout of a 7 day soft agar assay in AsPC-1, HPAC, and MIA PaCa-2 cell lines treated with 
the indicated constant concentration of the p38 inhibitor LY2228820 and a dose titration of 
the ERK inhibitor SCH772984.  Each growth assay is representative of n=3 experiments. 
Lower panels, quantification of AlamarBlue growth curves shown in each upper panel B, 
presented as fold GI50 shift, n=3 assays.  GI50 values are presented as mean ± SEM. 
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Figure 3-4. Concurrent inhibition of p38 and ERK induces G0/G1 cell cycle arrest and 
downregulation of markers of cell cycle progression. (A) AsPC-1, HPAC, and MIA 
PaCa-2 cells were treated with LY2228820 (2 µM), SCH772984 (625 nM), or combination 
for 72 h before staining with propidium iodide (PI) and Annexin V-FITC and analysis by flow 
cytometry. (B) Quantification of cells from (A) represented as the percentage of cells in each 
quadrant:  PI-,Annexin V- (healthy); PI+,Annexin V- (necrosis); PI-, Annexin V+ (early 
apoptosis); PI+, Annexin V+ (late apoptosis). (C)  AsPC-1, HPAC, and MIA PaCa-2 cells 
treated as in (A). Western blot analyses were performed for phosphorylated and total ERK, 
RSK, p38 and HSP27 as well as phosphorylated Rb, total MYC, Cyclin B1, Cyclin D1, p16, 
and PARP.  Vinculin levels were determined to verify equivalent loading of total cellular 
protein. (D) AsPC-1, HPAC, and MIA PaCa-2 cells treated as in (A) and stained with 
propidium iodide for total DNA content.  Graphs represent the percentage of cells in G0/G1, 
S, and G2/M of the cell cycle. 
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Figure 3-5.  Inhibition of ERK causes increased signaling through the p38 pathway.  
(A) AsPC-1, HPAC, and MIA PaCa-2 cell lines were treated with the indicated 
concentrations of SCH772984 for 24 or 72 h.  Western blot analyses were performed for 
phosphorylated and total ERK, RSK, MKK3/6, p38 and HSP27 as well as total MYC.  
Vinculin levels were determined to verify equivalent loading of total cellular protein.  (B)  
AsPC-1, HPAC, and MIA PaCa-2 cell lines were treated with the indicated concentrations of 
SCH772984 for 24 h.  Taqman quantitative PCR was performed to monitor changes in 
HSPB1 (HSP27) gene transcription and β-actin was used as an endogenous control. 
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Figure 3-6.  Concurrent inhibition of p38 enhances the loss of MYC protein induced by 
ERK inhibitor SCH772984. (A) AsPC-1 cells were co-treated with LY2228820 and 
SCH772984 at the indicated concentrations and times. Western blot analyses were done for 
phosphorylated and total ERK, RSK, MKK3/6, p38, MK2 and HSP27, and total MYC and 
vinculin. (B)  AsPC-1 cells were co-treated with LY2228820 and SCH772984 at the 
indicated concentrations for 24 h. Western blot analyses were done for phosphorylated and 
total ERK, RSK, MKK3/6, p38, MK2 and HSP27, and total MYC and vinculin. (C) AsPC-1 
cells were co-treated with LY2228820 and SCH772984 at the indicated concentrations for 6 
or 24 h. Taqman quantitative PCR was performed to monitor changes in MYC gene 
transcription and β-actin was used as an endogenous control. 
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Figure 3-7. Concurrent inhibition of p38 also enhances the reduction in anchorage-
dependent and -independent growth induced by ERK inhibitor BVD-523. (A) 72 h MTT 
assay of AsPC-1, HPAC, and MIA PaCa-2 cell lines treated with indicated concentrations of 
the p38 inhibitor LY2228820 and dose titration of the ERK inhibitor BVD-523.  Each growth 
assay is representative of n=3 experiments. Lower panels show compiled MTT assay 
results, represented as fold GI50 shift, n=3 assays. (B)  AsPC-1, HPAC, and MIA PaCa-2 cell 
lines were treated with the indicated concentrations of BVD-523 for 24 or 72 h.  Western blot 
analyses were performed for phosphorylated and total ERK, RSK, MKK3/6, p38 and HSP27 
as well as total MYC.  Vinculin levels were determined to verify equivalent loading of total 
cellular protein.   
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Figure 3-8.  Concurrent inhibition of p38 can enhance ERK inhibitor treatment-
induced loss of MYC protein. HPAC cells (A) and MIA PaCa-2 cells (B) were co-treated 
with LY2228820 and SCH772984 at the indicated concentrations and for the indicated 
times. Western blot analyses were done for phosphorylated and total ERK, RSK, MKK3/6, 
p38, MK2 and HSP27, and total MYC and vinculin. 
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Figure 3-9.  Concurrent p38 and ERK inhibition does not regulate MYC protein post-
translationally or regulate MYC transcript stability.  (A) AsPC-1 cells were treated with 
LY2228820 (2 µM), SCH772984 (625 nM), or combination in the presence of cycloheximide 
(50 µg/ml). Lysates were probed for MYC, pRSK and total RSK, and pHSP27.  Vinculin 
served as a loading control. (B) Densitometric calculation of MYC protein levels from blot in 
(A). (C) AsPC-1 cells were treated with LY2228820 (2 µM), SCH772984 (625 nM), or 
combination in the presence of Actinomycin D, and quantitative PCR analysis of MYC 
mRNA was performed. 
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Chapter IV: CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
 
SUMMARY AND CONCLUSIONS 
 
 My work has addressed the role of ERK in both melanoma and pancreatic 
cancers harboring either RAS or RAF mutations.  The RAF-MEK-ERK protein kinase 
cascade is one of the best characterized effector pathways downstream of RAS and 
has been the focus of pharmaceutical development at each node of the pathway, 
with inhibitors approved or in clinical trials for inhibition of RAF, MEK, or ERK.  First, 
I used pharmacologic inhibitors of RAF, MEK or ERK to interrogate the role of ERK 
and showed that ERK drives the overexpression of PREX1 in both NRAS- and 
BRAF-mutant melanoma.  Second, I extended my studies of pharmacologic 
inhibition of ERK to KRAS-mutant pancreatic cancer, as our lab has shown ERK 
inhibition to be an effective treatment for a subset of PDAC, and I identified MAPK14 
(p38α) as a novel sensitizer to ERK inhibition.  Pharmacologic inhibition of p38α/β 
with the clinical candidate inhibitor LY2228820 sensitizes PDAC cell lines to the ERK 
inhibitor SCH772984, and treatment with SCH772984 leads to the activation of the 
p38 MAPK cascade.  Although my work has shown the importance of ERK in 
melanoma and PDAC, there are many unanswered questions about the role of ERK 
in each cancer type. 
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FUTURE DIRECTIONS 
 
 
What transcription factor regulates PREX1 expression in NRAS- and BRAF- 
mutant melanomas? 
 My work demonstrates that ERK regulates the expression of PREX1 at both a 
transcriptional and post-transcriptional level in NRAS- and BRAF-mutant 
melanomas.  However, the transcription factor that regulates PREX1 downstream of 
ERK in melanoma has not been identified.  ERK1/2 can phosphorylate greater than 
200 known substrates, including transcription factors such as MYC and ELK-1[142].  
Previous work identified the transcription factor specificity factor 1 (SP1) as the 
regulator of PREX1 expression in prostate cancer and subsequent work found that 
SP1 also regulates PREX1 in breast cancer[125,150].  ERK directly phosphorylates 
SP1 and regulates its binding  to DNA and transcriptional activity[185].  However, in 
both NRAS- (SK-MEL-119, Mel224) and BRAF-mutant (A375, WM2664) melanoma 
cell lines, knockdown of SP1 did not regulate the expression of PREX1 transcript 
(Figure 4-1A).  This supports my previous findings that PREX1 overexpression in 
melanoma is regulated by a different mechanism than in either breast cancer or 
prostate cancer.  
 To further interrogate the question of how ERK regulates PREX1 
transcriptionally, I also investigated additional transcription factor candidates.  
Microphthalmia-associated transcription factor (MITF) and MYC are two transcription 
factors which have been found to be regulated by ERK phosphorylation, with MITF 
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in particular playing a role in melanoma development[151,186,187].  I knocked down both 
MITF and MYC individually with shRNA in a panel of NRAS- and BRAF-mutant 
melanoma cell lines.  As was seen with SP1, loss of either MITF or MYC did not 
reduce PREX1 mRNA levels; however, in the NRAS-mutant cell line SK-MEL-119, 
loss of MYC did reduce PREX1 protein and mRNA (Figure 4-1B,C).  In future, to 
address what transcription factor regulates PREX1 expression downstream of ERK 
in NRAS- and BRAF-mutant melanoma, I would perform a promoter analysis using a 
luciferase driven reporter as described in Wong et al.[125].  Using fragments of the 
PREX1 reporter region, the binding sites of potential transcription factors can be 
identified.  The individual candidate transcription factors can then be knocked down 
in a panel of NRAS- and BRAF-mutant melanoma lines and transcription of 
endogenous PREX1 can be measured by Taqman quantitative PCR.  I would look 
for loss of transcription factor phosphorylation in the presence of ERK inhibitor. 
 
Does PREX1 contribute to resistance to ERK MAPK cascade inhibitors? 
 One major issue facing efforts to successfully target the ERK MAPK cascade 
is inhibitor resistance, both innate and acquired.  Multiple mechanisms of resistance 
to ERK MAPK cascade inhibitors, RAFi or MEKi, have been identified, including 
those that re-activate ERK or those that activate other pathways through kinome 
reprogramming[133].  Two identified potential mechanisms of resistance to the RAF 
inhibitor vemurafenib are mutations in PREX2, a related isoform to PREX1, and 
mutational activation of RAC1 at the P29 locus[102,188,189].  My studies confirmed that 
PREX1 regulates RAC1 activity and that RAC1 is a major regulator of invasion. 
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Under short term treatment with ERK MAPK pathway inhibitors, PREX1 expression 
is reduced, but the effect of long term ERK inhibition on PREX1 expression has not 
been explored. 
 In order to address the role of PREX1 in long term ERK MAPK inhibitor 
treatment, I would treat both NRAS- and BRAF-mutant melanoma lines with low 
doses of inhibitor (at the growth EC50), gradually increasing inhibitor concentration 
over time until a resistant population of cells grew out.  I would then look at PREX1 
protein and transcript levels as well as RAC1-GTP levels in the resistant cell 
population compared to the parental cell lines.  I hypothesize that PREX1 transcript 
and protein expression would rebound and that RAC1-GTP levels would be 
increased in the resistant cell population.  There is also the question of whether loss 
of PREX1 would sensitize melanoma cell lines to ERK MAPK pathway inhibitors.  As 
I demonstrated, loss of PREX1 alone does not have an effect on proliferation of 
melanoma cell lines.  To address the question of whether loss of PREX1 would 
sensitize cells to inhibitors of the ERK MAPK cascade, I would knock down PREX1 
using siRNA and then treat NRAS-mutant melanoma cells with either trametinib or 
SCH772984 and BRAF-mutant melanoma cells with either vemurafenib or 
SCH772984.  I would then compare the EC50 and GI50 of growth between the 
mismatch (MM) and PREX1 siRNA treatment conditions and would predict that loss 
of PREX1 would shift both the EC50 and GI50 of melanoma cell line growth. 
Do novel ERK inhibitors behave similarly to SCH772984? 
 Pancreatic ductal adenocarcinoma (PDAC), like melanoma, has been found 
to be dependent on the ERK MAPK cascade and can develop resistance to therapy.  
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However, only a subset of PDAC cell lines are sensitive to the ERK inhibitor 
SCH772984 while other cell lines display innate resistance to ERK inhibition[148].  My 
work has shown that one potential mechanism of resistance to SCH772984 is the 
p38 MAPK pathway and that treatment with the p38 inhibitor LY2228820 can 
sensitize PDAC cell lines to ERK inhibition.  However, the status of SCH772984 as a 
clinical candidate ERK inhibitor going forward is uncertain, presenting a need for 
studying the efficacy of novel ERK inhibitors in PDAC.  Currently, two additional ERK 
inhibitors are under clinical evaluation.  It will be interesting to determine if p38 
inhibition can also modulate the sensitivity of PDAC to these ERK inhibitors. 
We utilized a novel ERKi whose structure and mechanism of action are 
distinct from those of SCH772984.  Preliminary experiments with that inhibitor have 
shown that it exerted a similar growth suppression on plastic of MIA PaCa-2 and 
Pa14c compared to SCH772984 (Figure 4-2A).  When expanded to a larger panel of 
both established and PDX PDAC cell lines, SCH772984 and the novel ERKi 
exhibited similar inhibition of growth on plastic, as measured by GI50 of growth 
(Figure 4-2B).  Even though the growth inhibitory effects were similar between the 
two inhibitors, the novel ERKi and SCH7772984 may inhibit ERK activity with 
different dynamics and/or consequences.  To address this question, I treated Pa14c 
cells with either the novel ERKi or SCH772984 for 4 or 24 h, because previous 
studies have shown a rebound of ERK phosphorylation by 24 h upon treatment with 
other ERKi[60,148].  Both inhibitors effectively reduced phosphorylation of RSK and 
reduced total levels of MYC to a similar degree with similar dynamics, while also 
causing a compensatory increased phosphorylation of MEK, the kinase immediately 
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upstream of ERK (Figure 4-2C).  However, only SCH772984, which has both an 
ATP-competitive and an allosteric mechanism of action, blocked ERK 
phosphorylation by MEK, and it did so at both 4 and 24 h, whereas the novel ERKi 
failed to prevent ERK phosphorylation at either time point.  This finding suggests that 
the novel ERKi is not able to forestall the paradoxical activation of ERK observed 
with earlier generation ERK inhibitors [59] and is less likely than SCH772984 to be 
effective at inhibiting growth long term. 
Thus, although short term growth assays and signaling effects were similar 
between SCH772984 and the novel ERKi, both the duration of response and 
mechanisms of resistance may differ between these and other ERK inhibitors.  I 
have identified p38 as a potential mechanism of resistance to SCH772984 and 
would extend the study to additional ERK inhibitors, such as the novel ERKi.  First, 
would LY2228820 also sensitize PDAC cell lines to the novel ERKi, both on plastic 
and in soft agar?  Second, would treatment with the novel ERKi activate the p38 
MAPK pathway?  I would address these questions by performing both MTT and soft 
agar assays as well as Western blot analysis, respectively, as described in the 
methods of Chapter 3.  Additional mechanisms of resistance can be identified by a 
broader screening approach.  One approach to identify potential mechanisms of 
resistance to the novel ERKi would be a CRISPR/Cas9-based loss-of-function 
genetic screen, as described in Chapter 3 for SCH772984, while a second approach 
would be drug sensitivity and resistance testing (DSRT), using a library of clinical 
inhibitors to identify synergy with ERKi[112].  The DSRT screening utilizes a library of 
clinical candidate or approved inhibitors for large scale combinatorial studies to 
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identify potential synergy between compounds in the library and a candidate inhibitor 
of interest, such as the novel ERKi. 
What are the roles of ERK1 and ERK2 in PDAC? 
 I have shown that pharmacologic inhibition with three different ERK inhibitors, 
SCH772984, BVD-523, and a novel ERKi, reduces KRAS-mutant PDAC growth, and 
that both SCH772984 and BVD-523 can synergize with the p38 inhibitor LY2228820.  
However, there is an outstanding question of what the differential roles of ERK1 and 
ERK2 are in driving PDAC growth.  ERK1 and ERK2 share high sequence identity, 
with 86% and 88% total sequence identity and kinase domain identity, respectively, 
and are thought to have some functional redundancy[142,190,191].   However, it has 
been demonstrated that genetic knockouts of ERK1 or ERK2 yield strikingly different 
results in mouse models; loss of ERK1 results in viable offspring while loss of ERK2 
is embryonic lethal, indicating that ERK1 activity is not sufficient to rescue loss of 
ERK2[192,193].  Recent evidence has also suggested alternate roles for ERK1 and 
ERK2 in maintenance of ERK/MAPK-dependent tumors. Loss of either ERK1 or 
ERK2 was sufficient to cause reduced proliferation in vitro in both mesothelioma and 
BRAF-mutant melanoma, including induction of apoptosis in melanoma; however, it 
was loss of ERK2 that reduced tumor formation and growth in vivo in 
mesothelioma[194,195].   
 In order to study the roles of ERK1 and ERK2 in KRAS-mutant PDAC, I have 
employed a genetic knockdown approach to study each isoform individually.  Using 
shRNA to selectively knockdown ERK1 (MAPK3) or ERK2 (MAPK1), with two 
independent shRNAs per gene, I was able to successfully knock down ERK1 and 
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ERK2 protein expression in a panel of PDAC cell lines, and to confirm that each 
shRNA was specific for its respective isoform (data not shown).  With the exception 
of the Capan-1 cell line, loss of either ERK1 or ERK2 was sufficient to inhibit 2D 
clonogenic growth of PDAC cells on plastic (Figure 4-3).  This finding of reduced 
PDAC growth upon genetic knockdown of either ERK1 or ERK2 also extended to 
colony formation in a 3D soft agar assay (data not shown).  Collectively, my 
preliminary data show strong evidence for differential roles for ERK1 and ERK2 in 
sustaining PDAC growth, with each isoform unable to compensate for the loss of the 
other.   
 To further interrogate the role of ERK1 and ERK2 in maintenance of KRAS-
mutant PDAC growth, I would use shRNA knockdown of expression to identify 
substrates regulated downstream of ERK1 or ERK2.  First, a candidate approach 
using phosphor-specific antibodies can be used to identify ERK1 or ERK2 regulated 
substrates, including transcription factors (FosS374, JunS63, STAT1S727, STAT3S727), 
adhesion- and motility-related proteins (FAKS910, PAK1T212, PaxillinS383), and ERK 
regulatory proteins (MKP1/2S359)[196-201].  To approach identification of ERK1- or 
ERK2-selective substrates in an unbiased fashion, I would employ a SILAC (stable 
isotope labeling by amino acids in cell culture) based mass spectrometry approach 
to identify phosphorylated proteins downstream of ERK1 and/or ERK2 (Figure 4-4).  
I would selectively knock down ERK1, ERK2 or both isoforms using a doxycycline 
(DOX) inducible shRNA vector system[202], which I have optimized for use with ERK1 
and ERK2 shRNA sequences in PDAC cell lines (data not shown).  Use of a DOX 
inducible knockdown system can allow for control of ERK knockdown in a dose- and 
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time-dependent manner, while a SILAC labeling approach would allow for -DOX 
(Light Lysine/Arginine) and +DOX (Heavy Lysine/Arginine) conditions to be directly 
compared in the same mass spectrometry run.  Bioinformatics sequence analysis 
would be done using databases such as PHOSPHOSITE and SCANSITE to filter 
results for proteins containing either the DEF or DEJL docking domains for ERK, as 
well as the putative ERK phosphorylation site Pro-X-Ser/Thr-Pro. ERK1- and/or 
ERK2-selective substrates identified by mass spectrometry can then be validated by 
Western blot analysis of those phosphorylated substrates  
 
Do p38 and ERK1/2 share common downstream substrates in PDAC and do 
p38α and p38β have overlapping functions? 
p38, much like ERK, is the terminal node of a MAPK cascade and is 
represented by two isoforms, MAPK14 (p38α) and MAPK11 (p38β), that are often 
assumed to have redundant functions in phosphorylating and regulating their many 
downstream substrates[191].  The p38 inhibitor LY2228820 can inhibit both p38α and 
p38β to a similar degree[168], so a genetic knockdown approach would have to be 
employed to study the specific role of each isoform in sensitization of PDAC to ERK 
inhibition.  First, I would use siRNA to selectively knock down MAPK14 or MAPK11 
or both isoforms concurrently.  I would treat the PDAC knockdown cell lines with 
SCH772984 to see if loss of one or both isoforms can also sensitize cells to ERK 
inhibitor in anchorage-dependent (MTT) and anchorage-independent (soft agar) 
growth assays. 
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My results shown in Chapter 3 demonstrate that p38 and ERK inhibitors can 
synergize in PDAC, potentially through a cell cycle arrest mechanism both 
dependent on and independent of MYC downregulation.  However, the connection 
between the two pathways is not known beyond a potential connection to MYC, as 
seen in the AsPC-1 cell line.  I would apply the phospho-proteomics approach 
described for studying the ERK1 and ERK2 isoforms to studying the effects of 
SCH772984, LY222820, or combination treatment in AsPC-1, HPAC, and MIA 
PaCa-2.  I would compare the phospho-proteome profile between the three 
treatment conditions to identify potential shared candidate substrates that are either 
downregulated or upregulated in response to inhibitor treatment.  Alternatively, 
reverse phase protein array (RPPA) can be applied for a discrete set of substrates 
downstream of the ERK and/or p38 MAPK cascades and other phosphorylated and 
total proteins of interest[203].  Collectively, these techniques would reveal a 
connection, or multiple downstream connections, between ERK and p38 that  
regulates the response to combined inhibition of both pathways.  These proposed 
studies also have the potential to identify a biomarker that may be predictive of 
PDAC response to combined p38 and ERK inhibition. 
 
Would concurrent inhibition of ERK and p38 result in tumor regression in 
vivo? 
 My results have shown that the p38 inhibitor LY2228820 can enhance the 
anti-tumor effects of the ERK inhibitor SCH772984 in vitro.  However, does the 
synergy between p38 and ERK inhibitors hold true in vivo and does it result in a 
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cytotoxic or cytostatic response in PDAC tumors?  SCH772984 treatment alone 
resulted in tumor regression in some PDAC xenografts while reducing, but not 
stopping, tumor growth in others[148].  I would investigate whether the addition of 
LY2228820 would enhance the anti-tumor effect of SCH772984 in an orthotopic 
xenograft model, where the final volume of tumor from each treatment group would 
be compared. I could also employ a subcutaneous xenograft model, where I would 
monitor tumor growth over time. Concomitantly, I would also investigate whether 
treatment with an ERK inhibitor can induce p38 pathway activity in tumors in a 
similar fashion as seen in cell culture models and if phosphorylation of HSP27 is an 
accurate marker of LY2228820 activity in vivo. 
 Next, there is the question of what role p38 activation may be playing in 
human tumors in response to targeted therapy of the ERK cascade.  Given that ERK 
inhibitors are still in the early stages of clinical trials in all tumor types, and initial 
clinical trials in PDAC patients have recently begun (NCT02608229), it may be 
difficult at present to obtain the patient tissues needed to assess p38 in clinical 
tumor response and resistance in PDAC.  However, our CRISPR results suggest 
that p38 may play a role in sensitizing multiple KRAS-mutant cancer types, including 
lung and colorectal cancers, to both ERK and MEK inhibitors. I hypothesize that p38 
phosphorylation and pathway activation in response to RAF, MEK, or ERK inhibitors 
is a common mechanism shared by RAS-driven cancers dependent on the pathway 
and can potentially be predictive of response to therapy in the clinic. 
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Figure 4-1.  Not all transcription factors known to be regulated by ERK regulate 
PREX1 transcription.  BRAF-mutant cell lines A375 and WM2664 and NRAS-mutant cell 
lines SK-MEL-119 and Mel224 were lentivirally transduced with RNAi, and PREX1 mRNA 
levels were measured by Taqman qPCR.  Cells were transduced with (A) nonspecific (NS) 
or SP1 shRNA; (B) nonspecific (NS) or MITF shRNA; or (C) mismatch (MM) or MYC siRNA. 
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Figure 4-2. ERK inhibitors SCH772984 and novel ERKi display similar growth 
inhibition and signaling effects in PDAC cell lines. (A) MIA PaCa-2 and Pa14c cells were 
treated with SCH77284 or ERKi for 72 h and viable cells were measured by MTT. (B) 
Calculations of GI50 for SCH77294 and ERKi in a panel of 5 established and 5 patient-
derived xenograft (PDX) KRAS-mutant PDAC cell lines. (C) Pa14c PDX cells were first 
treated with the indicated concentrations of SCH772984 or ERKi for 4 and 24 h, and lysates 
were immunoblotted for pERK, total ERK, pRSK, total RSK, MYC, pMEK and total MEK, 
with vinculin serving as a loading control. 
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Figure 4-3.  Loss of ERK1 or ERK2 reduces PDAC growth on plastic.  2D clonogenic 
assays, stained after 10 or 14 days, of KRAS-mutant PDAC cell lines after transduction with 
non-specific (NS), ERK1 or ERK2 shRNA.  Images of each well are representative of assays 
run in triplicate. 
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Figure 4-4. Phospho-peptide analysis workflow. 
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